WO2012123384A1 - Improvements to immobilised biological entities - Google Patents
Improvements to immobilised biological entities Download PDFInfo
- Publication number
- WO2012123384A1 WO2012123384A1 PCT/EP2012/054179 EP2012054179W WO2012123384A1 WO 2012123384 A1 WO2012123384 A1 WO 2012123384A1 EP 2012054179 W EP2012054179 W EP 2012054179W WO 2012123384 A1 WO2012123384 A1 WO 2012123384A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyperbranched polymer
- molecular weight
- heparin
- cationic
- hyperbranched
- Prior art date
Links
- 0 CCCCCCI(C[C@](*)CCIC)C(CN(CCN(CCN)CCN[*+])CCN(CCNCCN*)CCNI)N(CCN(CCN)CCN(CCN)CCN)CCN(CCNCCN)CCN(CCNCCN(CCN)CCNN)CCN(CCN)CCNCCN* Chemical compound CCCCCCI(C[C@](*)CCIC)C(CN(CCN(CCN)CCN[*+])CCN(CCNCCN*)CCNI)N(CCN(CCN)CCN(CCN)CCN)CCN(CCNCCN)CCN(CCNCCN(CCN)CCNN)CCN(CCN)CCNCCN* 0.000 description 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/068—Use of macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/452—Lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0035—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using a polymer with positively charged atoms in the polymeric backbone, e.g. ionenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0064—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0076—Chemical modification of the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/08—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L101/00—Compositions of unspecified macromolecular compounds
- C08L101/005—Dendritic macromolecules
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
- C08L79/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
- C08L79/04—Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors
- C08L79/08—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31971—Of carbohydrate
Definitions
- This invention relates to immobilised biological entities to devices having surface coatings comprising such entities, and processes and intermediates for their production.
- the invention relates to immobilised anti-coagulant entities such as heparin and to devices, for example medical, analytical and separation devices having surface coatings comprising immobilised heparin.
- Thrombin is one of several coagulation factors, all of which work together to result in the formation of thrombi at a surface in contact with the blood.
- Antithrombin also known as antithrombin III
- ATIN antithrombin III
- AT antithrombin III
- Heparin dramatically enhances the rate at which antithrombin inhibits coagulation factors.
- HIT thrombocytopenia
- Heparin is a polysaccharide carrying negatively charged sulfate and carboxylic acid groups on the saccharide units. Ionic binding of heparin to polycationic surfaces has been attempted, but these surface modifications tended to suffer from lack of stability over time resulting in lack of non-thrombogenic function, as the heparin leached from the surface.
- US 2005/0059068 relates to a substrate for use in microassays.
- An activated polyamine dendrimer is covalently bonded to the surface of the substrate through a silane containing moiety.
- the dendrimer has branch points which are tertiary amines and terminal residues which are NH 2 , OH, COOH or SH groups.
- Molecules containing OH or NH 2 functional groups can be bound to the dendrimer via the terminal residues of the dendrimer. Since the substrate is for use in microassays, it is usually a slide, bead, well plate, membrane etc. and the moiety containing the OH or NH 2 group is a nucleic acid, protein or peptide.
- WO 03/057270 describes a device, for example a contact lens, with a lubricious coating having high surface hydrophilicity.
- coating materials including glycosaminoglycans (e.g. heparin or chondroitin sulfate) and PAMAM dendrimers. PAMAM dendrimers are said to be among the preferred coatings.
- the document exemplifies a contact lens having multiple layers of PAMAM dendrimer and polyacrylamide-co-polyacrylic acid copolymer (PAAm-co-PAA). The coating is formed by consecutively dipping the contact lens into solutions of the two coating materials, with the outer layer being PAAm-co-PAA.
- US 2003/0135195 teaches a medical device such as a catheter with a highly lubricious hydrophilic coating formed from a mixture of colloidal aliphatic polyurethane polymer, an aqueous dilution of poly(1-vinylpyrrolidone-co-2-dimethylaminoethylmethacrylate)-PVP and dendrimers.
- the coating may be applied to the device by dipping the device in a colloidal dispersion of the aliphatic polyurethane polymer in a solution of poly(1- vinylpyrrolidone-co-2-dimethylaminoethylmethacrylate)-PVP and an active agent (e.g.
- heparin in a mixture of dendrimer, water, N-methyl-2-pyrrolidone and triethylamine.
- the document teaches that heparin may be contained in the voids within the dendrimers.
- the document also teaches that the loaded heparin will elute from the hydrophilic polymer matrix at a predetermined rate.
- US 2009/0274737 teaches implants such as stents having a hydrophilic surface with a wetting angle of ⁇ 80°.
- anticoagulants include heparin and certain dendrimers, especially sulphated dendrimers.
- the surface may be functionalised in order to bind the anticoagulant and examples of functionalization are silanization and reaction with 1 , 1 '- carbonyldiimidazole (CDI).
- US 4,944,767 relates to a polymeric material which is able to adsorb high quantities of heparin.
- the material is a block copolymer in which polyurethane chains are interconnected with polyamidoamine chains.
- WO 2010/029189 relates to a medical device having a coating with an anticoagulant molecule such as heparin covalently attached to the coating via a 1 ,2,3-triazole linkage.
- the document describes the azide or alkyne functionalisation of a polyamine; the preparation of alkyne or azide functionalised heparin (both native and nitrous acid degraded heparin); and the reaction to link the derivatised heparin to the derivatised polymer via a 1 ,2,3- triazole linker.
- Heparins have the ability to bind a wide variety of biomolecules including enzymes, serine protease inhibitors (such as antithrombin), growth factors and extracellular matrix proteins, DNA modification enzymes and hormone receptors. If used in chromatography, heparin is not only an affinity ligand but also an ion exchanger with high charge density. Thus biomolecules can be specifically and reversibly adsorbed by heparins immobilized on an insoluble support. Immobilised heparins therefore have a number of useful non-medical applications, particularly for analysis and separation.
- a device having a surface comprising a layered coating wherein the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80: 1 (e.g. at least 100:1) and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto.
- the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80: 1 (e.g. at least 100:1) and
- Figure 1 is a schematic representation in 2-D of different types of hyperbranched polymers in which A represents a polymer with branching points (theoretically) in every monomeric unit; B represents a branched polymer with linear backbone and branched wedges, called dendrons, attached to it; C represents a polymer with branching units incorporated into linear segments; and D represents a dendrimer.
- Figure 2 illustrates in 2-D an exemplary PAMAM dendrimer having 3 generations (in 3-D the structure would be approximately spherical).
- Figure 3 is a schematic illustration in 2-D of an exemplary second generation dendrimer in which the core has three reactive functional groups, all of which are substituted; the first layer has six reactive functional groups, all of which are substituted; and the second layer has twelve reactive functional groups.
- Such a dendrimer will adopt a substantially spherical shape in 3-D.
- Figure 4 illustrates how a first functional group on a heparin moiety (or other anti-coagulant entity) may be reacted with a second functional group which is an end group of the dendrimer or other hyperbranched polymer.
- Figure 5 shows how several dendrimers or other hyperbranched polymers may be cross-linked to each other prior to functionalisation by heparin or other anti-coagulant entity.
- Figure 6 shows how several dendrimers or other hyperbranched polymers which have been functionalised by heparin or other anti-coagulant entity may be cross-linked to each other.
- Figure 7 is a schematic representation of the components of the invention. It shows how the hyperbranched polymers, bearing anti-coagulant entities, in the outer coating layer interact (involving covalent bonds and/or ionic interactions) with the underlayer and other
- hyperbranched polymers in the outer coating layer are hyperbranched polymers in the outer coating layer.
- Figure 8 shows the percentage of platelets remaining in blood after contact with various non- thrombogenic coatings (see Example 6).
- Figure 9 shows an exemplary Toluidine blue staining of a PVC tube before and after coated with a heparin-containing coating according to the invention (see Example 3.2 and Example 6.3).
- plate A Before
- plate B After
- Figure 10 shows the percentage of platelets remaining in blood after contact with various non- thrombogenic coatings (see Example 11).
- An anti-coagulant entity is an entity capable of interacting with mammalian blood to prevent coagulation or thrombus formation.
- Anti-coagulant entities are well known to those skilled in the art and many of them are oligosaccharides or polysaccharides. Some of the entities are glycosaminoglycans including compounds containing glucosamine, galactosamine, and/or uronic acid. Among the most suitable glycosaminoglycans are "heparin moieties" and especially full length heparin (i.e. native heparin). The term "heparin moiety” refers to a heparin molecule, a fragment of the heparin molecule, or a derivative or analogue of heparin. Heparin derivatives can be any functional or structural variation of heparin.
- alkali metal or alkaline earth metal salts of heparin such as sodium heparin (e.g. Hepsal or Pularin), potassium heparin (e.g. Clarin), lithium heparin, calcium heparin (e.g. Calciparine), magnesium heparin (e.g. Cutheparine), and low molecular weight heparin (prepared by e.g. oxidative depolymerization or deaminative cleavage, e.g. Ardeparin sodium or Dalteparin).
- Other examples include heparan sulfate, heparinoids, heparin based compounds and heparin having a hydrophobic counter-ion.
- Other desirable anti-coagulant entities include synthetic heparin compositions referred to as
- “fondaparinux” compositions e.g. Arixtra from GlaxoSmithKline
- Additional derivatives of heparin include heparins and heparin moieties modified by means of e.g. mild nitrous acid degradation (US4, 613,665) or periodate oxidation (US 6,653,457) and other modification reactions known in the art where the bioactivity of the heparin moiety is preserved.
- Heparin moieties also include such moieties bound to a linker or spacer as described below.
- De-sulphated heparin, or heparin functionalized via e.g. the carboxylic acid group of the uronic acid moiety are less suitable than other forms of heparin because of their generally reduced anti-coagulant properties relative to other forms of heparin.
- Mono-functionalization or low functionalization degrees of carboxylic acid groups can be acceptable as long as heparin bioactivity is preserved.
- each anti-coagulant entity is single point attached to a hyperbranched polymer molecule, particularly end point attached. The attachment is via functional end groups on the hyperbranched polymer molecule as discussed below.
- the anti-coagulant entity When the anti-coagulant entity is an end point attached heparin moiety, it is suitably connected to the hyperbranched polymer molecule through its reducing end (sometimes referred to as position C1 of the reducing terminal).
- the advantage of end point attachment, especially reducing end point attachment is that the biological activity of the anti-coagulant entity (for example the heparin moiety) is maximized due to enhanced availability of the antithrombin interaction sites as compared with attachment elsewhere in the anti-coagulant entity (e.g. heparin moiety).
- anti-coagulant entities e.g. heparin moieties it is possible for some or all of them to be of a different type; however generally they will all be of the same type.
- Anti-coagulant entities are commonly anionic (as in the case of heparin moieties). Other anti-coagulant entities such as hirudin, Coumadins (vitamin K antagonists of the 4- hydroxycoumarin class like warfarin), anti-platelet drugs (as clopidogrel and abciximab), argatroban, thrombomodulin or anti-coagulant proteins (like proteins C, S or antithrombin) may also be considered for use. Anti-coagulant entities may also include enzymes such as apyrase. Such substances may be charged (e.g. anionic) or uncharged. The way these may be attached to the hyperbranched polymer so that its bioactivity is preserved can be designed by someone skilled in the art.
- FIG. 1 Examples of various types of hyperbranched polymers are shown schematically in Figure 1 , types A to D.
- A in Figure 1 , represents a polymer with branching points (theoretically) in every monomeric unit; B represents a branched polymer with linear backbone and branched wedges, called dendrons, attached to it; C represents a polymer with branching units incorporated into linear segments; and D represents a dendrimer.
- hyperbranched polymers useful in the context of the present invention if the core segment is sufficiently small in relation to the overall size of the molecule.
- the term "hyperbranched polymer molecule” is well understood in the art to refer to a molecule having a tree like branching structure emanating from a core moiety typically in the centre. In the context of the present invention, the term also includes dendrimers, which are well known and are hyperbranched polymer molecules in which the degree of branching is 100% (occasionally referred to herein as "perfectly branched” i.e. 100% of functional groups capable of branching are branched) and which are therefore highly symmetrical about the core.
- Hyperbranched polymers consist of three basic architectural components, (i) the core, (ii) the interior and (iii) the functional end groups.
- the core is positioned at the centre of the molecule and to it branched wedges, called dendrons, are attached.
- the dendrons may be perfectly branched or less than perfectly branched.
- the core of a hyperbranched polymer molecule is polyfunctional (either with several of the same type or several of different types of functionalities) and the number of functional groups it bears dictates the number of branches possible to be introduced in the molecule. Typically all functional groups of the core are utilized in branching.
- the shape of a hyperbranched polymer molecule is determined by the core shape, with substantially tetrahedral cores giving rise to substantially spherical hyperbranched polymer molecules and more elongated cores giving rise to ovoid or rod-shaped hyperbranched polymer molecules.
- the core moiety will be a relatively small entity in relation to the overall size of the polymer, having a molecular weight of between 14 and 1 ,000 Da, more usually between 40 and 300 Da and for example 50 to 130 Da.
- Dendrimers are perfectly branched molecules in which the degree of branching is 100%, thus their structure is highly regular and therefore, for a given starting material, the only variable is the number of layers or generations in the dendrimer. The generations are conventionally numbered outwards from the core. See, for example, Tables 2-4 below.
- Figure 2 illustrates a third generation dendrimer and Figure 3 illustrates a second generation dendrimer.
- the molecular weight distribution for dendrimers of a given generation is extremely narrow, which is highly advantageous as it leads to a very consistent product.
- Other hyperbranched molecules also contain a high number of branches, however, and, for example the degree of branching will usually be at least 30%, 40% or 50% for example at least 60%, 70%, 80% or 90%.
- the structure of such hyperbranched molecules will not be completely regular but they may also adopt a generally globular structure.
- the core is the moiety of a molecule which is not the same as the repeating unit(s) of the polymer. However in one embodiment the core is a moiety of the same type as the repeating unit (or one of the repeating units) of the polymer.
- Hyperbranched polymer molecules are generally prepared either by employing a divergent method, in which the layers are built up from a core, or a convergent method in which fragments are built up and then condensed. Dendrimers are more usually prepared using the divergent method.
- dendrimers In the synthesis of dendrimers a high degree of control over the addition reaction of every branching unit is essential and the resulting products show a polydispersity index (PDI) between 1.00 and 1.05.
- the dendron size depends on the number of monomer layers and every added layer is represented by a generation (G).
- G The interior consist of branching monomers that have ABx functionality where x ⁇ 2. Careful preparation of the branching unit makes it possible to control the reaction between A and B ' if B ' is the activated state of B. Larger dendrimers give rise to globular shaped, nanoscale sized, structures with low intrinsic viscosity as a result.
- dendrimers are synthesized by employing an iterative technique where ABx monomers are alternately added to the growing species followed by an activation/deprotection step. These protocols depend on efficient reactions that ensure full substitution of the terminal groups B ' . Any deviation will give structural defects that accumulate during dendrimer growth resulting in tedious or impossible purification procedures. See Aldrichimica Acta (2004) 37(2) 1-52 "Dendrimers: building blocks for nanoscale synthesis", herein incorporated in its entirety by reference, e.g. at pages 42-43 for further discussion of dendrimer synthesis and nomenclature.
- Hyperbranched polymers which are dendrimers with structural defects of this type can be used in this invention.
- Hyperbranched polymers which are not dendrimers may, for example, be formed by
- hyperbranched polymers which are polyamines may be prepared by polymerization of aziridine for example by treatment with base.
- Exemplarly core moieties include amines such as the moiety of ammonia (Mw 14 Da), diamines (e.g. ethylene diamine (Mw 56 Da), propylene diamine (Mw 70 Da) or 1 ,4-diaminobutane (Mw 84 Da)), and triamines (e.g.diethylenetriamine (NCH 2 CH 2 NHCH 2 CH 2 N) (Mw 99 Da) or 1 ,2,3- triaminopropane (89Da)).
- Other cores may be oxygen containing including C(Me)(CH 2 0) 3 (Mw 1 17 Da) or sulfur containing including (NCH 2 CH 2 S-SCH 2 CH 2 N) (Mw 148 Da).
- Cationic hyperbranched polymers will have a predominantly positive charge at about pH 7 that is to say that they either contain only uncharged groups and charged groups having positive charge at pH 7 or else (less preferred) have groups that are negatively charged at pH 7 that are outnumbered by groups that are positively charged.
- Cationic hyperbranched polymers of this invention typically will have primary amines as functional end groups.
- Hyperbranched polymers of use according to the invention may contain a number of functionalities for example they may be polyamines (entirely or substantially containing secondary and tertiary amine groups and with primary amines as functional end groups), polyamidoamines (amide groups and secondary and tertiary amine groups and with primary amines as functional end groups) or polyethers with amine functionality (e.g. polyethers such as PEGs in which end groups have been transformed into primary amine groups).
- An exemplary family of hyperbranched polymers are the polyamidoamines (PAMAMs) in which a moeity of ammonia or a di- or tri-amine (e.g. ethylenediamine) may be used as the core moiety and the addition of generations of the branched molecule may be built up by reacting the ammonia or the free amine groups with e.g. methyl acrylate followed by ethylene diamine leading to a structure having a number of free amine groups on the outer surface. Subsequent generations can be built up by further reaction with methyl acrylate and ethylene diamine. A structure in which all primary amine groups of the inner layers have been reacted with methyl acrylate and ethylenediamine will be a dendrimer.
- PAMAM dendrimers are available under the trade mark Starburst ® , manufactured by Dendritech Inc. Starburst dendrimers are sold by Dendritech Inc., Sigma Aldrich and Dendritic Nanotechnologies (D
- hyperbranched polymers may include polyamines such as polypropyleneimine (PPI) and polyethyleneimine (PEI) polymers formed by polymerization of the respective building blocks.
- PPI polypropyleneimine
- PEI polyethyleneimine
- Hyperbranched polymers based on PPI may also be synthesized from a core such as diaminobutane and built up by reaction of the primary amine groups with acrylonitrile followed by hydrogenation.
- PPI dendrimers are available under the trade mark AstramolTM and provided by DSM and Sigma Aldrich.
- Polyethyleneimine (PEI) polymers are available from e.g. BASF, Nippon Shokubai and Wuhan Bright Chemical.
- the hyperbranched polymer may be selected from polyamidoamine, polypropyleneimine, polyethyleneimine and other polyamine polymers and copolymers comprising one or more of polyamidoamine, polypropyleneimine, polyethyleneimine and polyamine hyperbranched polymers.
- cationic hyperbranched polymers having primary amine groups as functional end groups for example PAMAMs or polyethylenimines or polypropyleneimines, are particularly suitable for use in the present invention.
- Hyperbranched aminated polymers comprising esters, carbonates, anhydrides and
- polyurethanes are less suitable as they tend to degrade.
- biostability can depend on the number and proportion of biodegradable groups and some may therefore be suitable within this invention.
- the PAMAM illustrated in Figure 2 is based on ethylenediamine as core moiety.
- the properties according to the number of generations built up are described in Table 2 below:
- Scheme 1 Synthesis of a PAMAM-G0 dendrimer.
- a is methyl acrylate and b is ethane-1,2-diamine.
- Scheme 2 Synthesis of a PEI hyperbranched polymer.
- Synthesis of an exemplary PPI dendrimer based on butane, 1 ,4-diamine core by polymerization of acrylonitrile is shown in Scheme 3.
- the hyperbranched polymer molecules useful in the present invention typically have a molecular weight of about 1 ,500 to 1 ,000,000 Da, more typically about 10,000 to 300,000 Da e.g. about 25,000 to 200,000 Da.
- the hyperbranched polymer molecules useful in the present invention suitably are substantially spherical in shape. Typically they have a diameter of about 2 to 100 nm, e.g. 2 to 30 nm, especially about 5 to 30 nm as determined by laser light scattering.
- the hyperbranched polymer is a PAMAM dendrimer, it typically has a molecular weight of about 5,000 to 1 ,000,000 Da, more typically about 12,000 to 125,000 Da and a diameter of about 1 to 20 nm, e.g. 2 to 10nm, especially about 4 to 9 nm.
- the ratio of total molecular weight to core moiety molecular weight is at least 80: 1 , for example at least 100: 1 , for example at least 200:1 e.g. at least 500: 1 e.g. at least 1000:1.
- the ratio is typically less than 20,000: 1 e.g. less than 10,000: 1 e.g. less than 5,000:1.
- the ratio is between 80: 1 and 20,000:1 e.g. 200: 1 and 5,000: 1 e.g. between 200: 1 and 1600: 1 e.g. between 400:1 and 1600:1.
- the total molecular weight of the hyperbranched polymer referred to herein excludes the weight of any covalently attached anti-coagulant entity or any beneficial agent.
- the ratio is dictated by the molecular weight of the core and the total molecular weight of the hyperbranched polymer.
- the calculated ratio will vary as the core varies (in terms of chemical composition and molecular weight) and as the molecular weight of the generations varies (in terms of molecular weight of monomers and number of monomers attached in each
- a core derived from ethane-1 ,2-diamine is preferred and the number of generations is preferably between 3 and 10, more preferably between 4 and 7 i.e. 4, 5, 6 or 7.
- the plurality of cationic hyperbranched polymer molecules may optionally be cross-linked to one another on the surface of the device.
- Cross- linking may take place either before or after the hyperbranched polymer molecules are applied to the surface of the device and either before or after the anti-coagulant entities are attached thereto (see Figures 5, 6).
- the number of molecules that may be cross-linked to form an aggregate hyperbranched polymer is two or more and, for example, from 2-500 e.g. from 2-10 such as from 2-5; and each molecule may be attached to another molecule in the aggregate by one or more cross-linkages e.g. up to 10 cross linkages.
- Aggregates of 2 or more hyperbranched polymer molecules useful in the present invention typically have a molecular weight of about 3,000 to 2,000,000 Da, more typically about 50.000 to 500,000 Da.
- the hyperbranched polymer aggregates useful in the present invention typically have a diameter of about 5 to 100 nm, especially about 20 to 100 nm.
- Hyperbranched polymer molecules have a large number of functional end groups which can be reacted with anti-coagulant entities such as heparin (see Figure 4).
- the functional end groups can be of the same type or of several different types, as appropriate. Therefore, one of the advantages of the present invention is that it is possible to design the molecule such that it has a required number of functional end groups of a specific functionality. This makes it possible to selectively immobilize the desired amount of anti-coagulant entities on the surface of a device without interfering with the build up of the underlying layers.
- the branching structure of the hyperbranched molecules makes it possible to obtain a higher surface density of anti-coagulant entities than was possible using essentially linear polymer structures, while still achieving sufficient spacing of those anti-coagulant entities to ensure that the bioavailability of each entity is not reduced in comparison with that achieved using previously known coatings and may actually be increased.
- hyperbranched polymers Another useful feature of hyperbranched polymers is that the majority of the reactive functional end groups are on the surface of the hyperbranched molecule and therefore substantially all of the anti-coagulant entity is available on the surface of the hyperbranched polymer. The effect is particularly marked in the case of dendrimers, where all of the available functional groups are on the surface.
- This feature gives a particular advantage over conventional coating polymers in which many of the reactive functional end groups may be hidden in the interior of the structure rather than on the surface. This means that anti-coagulant entity which reacts with functional groups in such conventional coating polymers may be immobilized in the interstices of the polymer surface and will not be bioavailable.
- the derivatised hyperbranched polymer architecture will allow a more homogenous distribution of the anti-coagulant entity throughout the layers in which it is incorporated, such as the outer coating layer, which should, in principle, result in increased ageing stability. Further, the possibility of selecting and adjusting the anti-coagulant density on the hyperbranched polymer will allow for a more robust and predictable anti-coagulant distribution on the device.
- the pre- fabrication of the hyperbranched polymer-anti-coagulant entity conjugate also allows a lower batch to batch variability, since it is easier to adjust the degree of substitution of the
- hyperbranched polymer by the anti-coagulant entity (e.g. heparin) in solution rather than on a surface.
- the anti-coagulant entity e.g. heparin
- a cationic hyperbranched polymer molecule characterized by having (i) a core moiety of molecular weight 14-1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80:1 (e.g. at least 100:1) and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto.
- the cationic hyperbranched polymer may have a net positive or a net negative charge.
- the anti-coagulant entity has a covalent connection only to a single functional end group on one hyperbranched polymer molecule and not to any other molecule.
- the coupling of the anti-coagulant entity is never to the core of the hyperbranched polymer, only to a functional end group of the hyperbranched polymer.
- the number of functional end groups which have an anti-coagulant entity covalently attached thereto is one or more, for example 2 or more, for example 2 to 200 e.g. 10 to 100 however there is no specific upper limit.
- the number that may be attached will depend on the number of end groups that are available, which is a function of the size of the cationic hyperbranched polymer molecule.
- the number of functional end groups which have an anti-coagulant entity covalently attached thereto may for example be 1 to 95% e.g. 5 to 95% e.g. 10 to 80% e.g. 10 to 50% of available functional end groups.
- the number of functional end groups which have an anti-coagulant entity covalently attached thereto may for example be 5 to 50% e.g. 5 to 40% e.g.
- the anti-coagulant entities are anionic (for example, in the case of heparin moieties), the number that may be attached will also depend on whether it is desired for the resultant derivatised hyperbranched polymer to have a net positive charge (in which case there should not be too many anionic anticoagulant entities covalently attached) or a net negative charge.
- each anti-coagulant entity is covalently connected to a cationic hyperbranched polymer via a linker and optionally one or more spacers.
- the linker is formed by the reaction of a functional end group on the hyperbranched polymer with a functional group on the anticoagulant entity.
- Table 3 and Scheme 4 show examples of some types of linkers suitable for attaching the anti-coagulant entity to the hyperbranched polymer along with the functional groups from which the covalent linker is formed and the type of reaction used. See e.g.
- one of the functional end groups is on the hyperbranched polymer and the other is on the anti-coagulant entity.
- functional groups 1 and 2 may respectively be on the hyperbranched polymer and on the anti-coagulant entity or may respectively be on the anti-coagulant entity and on the hyperbranched polymer.
- the anti-coagulant entity and the hyperbranched polymer may be joined by a linker which comprises more than one functional group.
- a bifunctional molecule (having, for example an SH group at each end) can be connected at each end, respectively, to an alkyne/alkene functionalized anti-coagulant entity and an alkyne/alkene functionalized hyperbranched polymer molecule resulting in the linker containing two thioethers.
- a bis-alkyne/alkene molecule can be connected at each end, respectively, to a thiol functionalized anti-coagulant entity and a thiol functionalized hyperbranched polymer also resulting in the linker containing two thioethers. Similar possibilities exist for other linker types, as is clear from Table 3.
- the hyperbranched polymer may also carry two or more different functional groups, for example amine and alkyne functionality, so that anti-coagulant entities may be attached to the functional end groups of the hyperbranched polymer via more than one type of linker, however, we prefer attaching anticoagulant entity using one type of linker.
- functional groups for example amine and alkyne functionality
- the linker moiety will typically have a molecular weight of around 14 to 200 e.g. 14 to 100 Da. Table 3
- Reductive amination also known as reductive alkylation, is a form of amination that involves the conversion of a carbonyl group to an amine linker via an intermediate imine (Schiff s base).
- the carbonyl group is most commonly a ketone or an aldehyde.
- Michael addition is the nucleophilic addition of a carbanion or another nucleophile (e.g. primary amine or thiol) to an alpha, beta unsaturated carbonyl compound. It belongs to the larger class of conjugate additions. This is one of the most useful methods for the mild formation of C-C bonds.
- Thio-bromo Thioether linkages are typically prepared by the alkylation of thiols. Thiols may react with bromide compounds to generate thioether linkages. Such reactions are usually conducted in the presence of base, which converts the thiol into the more nucleophilic thiolate.
- thioether linkages may be prepared by reaction of a first compound containing a thiol group with a second compound containing an alkene or an alkyne group.
- the first and second compounds can each be the hyperbranched polymer molecule and the anti-coagulant entity as appropriate.
- reaction takes place in the presence of a reducing agent such as tris(2- carboxyethyl)phosphine hydrochloride, or alternatively dithiothreitol or sodium borohydride, to avoid or reverse the effective of undesirable coupling of two thiol groups through oxidation.
- a reducing agent such as tris(2- carboxyethyl)phosphine hydrochloride, or alternatively dithiothreitol or sodium borohydride
- the reaction is initiated with a radical initiator.
- a radical initiator is 4,4'-azobis(4-cyanovaleric acid).
- Further examples are potassium persulfate, 2,2'- azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride, azobisisobutyronitrile (AIBN), 1 ,2-bis(2- (4,5-dihydro-1 H-imidazol-2-yl)propan-2-yl)diazene dihydrochloride, 2,2'-(diazene-1 ,2-diyl)bis(2- methyl-1-(pyrrolidin-1-yl)propan-1-imine) dihydrochloride, 3,3'-((diazene-1 ,2-diylbis(1-imino-2- methylpropane-2, 1-diyl))bis(azanediyl))dipropanoic acid tetrahydrate, benzophen
- reaction is not initiated with a radical initiator. Instead, conditions of higher pH (e.g. pH 8-1 1) are used. This type of reaction is more suitable when an activated alkene or alkyne is used for reaction with the thiol.
- reaction between a first compound containing a thiol group and a second compound containing an alkyne group may be represented as follows:
- R a and R b is the hyperbranched polyamine and the other of R a and R b is the anti- coagulant entity.
- this compound may undergo a further chemical transformation with e.g. a thiol (as shown in Table 3) or an amine.
- an activated alkene is used.
- An example of a suitable activated alkene is a maleimide derivative.
- reaction between a first compound containing a thiol group and a second compound containing a maleimide group may be represented as follows:
- R a and R b is the polymer and the other of R a and R b is the anti-coagulant entity.
- the reaction is generally carried out in the presence of tris(2-carboxyethyl)phosphine hydrochloride as reducing agent, and 4,4'-azobis(4-cyanovaleric acid) as radical initiator, and under acidic conditions.
- Azide-Alkyne: 1 ,2,3-triazole linkages may be prepared by reaction of an alkyne and an azido compound.
- the reaction to form the linker may be between an alkyne group on one of the anticoagulant entity and the hyperbranched polymer molecule and an azido group on the other of the anti-coagulant entity and the hyperbranched polymer molecule. Methods for carrying out this reaction are similar to the methods described in WO 2010/029189.
- the reaction between the azide and the alkyne groups may be carried out at elevated temperatures (T>60°C) or in the presence of a metal catalyst, for example a copper, e.g. a Cu(l) catalyst using reaction conditions conventionally used in the Huisgen cycloaddition (the 1 ,3-dipolar cycloaddition of an azide and a terminal alkyne to form a 1 ,2,3-triazole).
- the Cu(l) catalyst may, if desired, be produced in situ, e.g. by reduction of a corresponding Cu(ll) compound for example using sodium ascorbate.
- the reaction may also, if desired, be carried out under flow conditions.
- the CuAAC reaction may, for example be carried out at a temperature of from about 5 to 80 °C, preferably at about room temperature.
- the pH used in the reaction may be from about 2-12, preferably about 4-9 and most preferably at about 7.
- Suitable solvents include those in which the entity attached to the azide or alkyne is soluble, e.g dimethylsulfoxide,
- the proportion of the entity to the surface may be adjusted to provide the desired density of the entity on the surface.
- Amides are commonly formed via reactions of a carboxylic acid with an amine. Carboxylic acids and carboxylic acid derivatives may undergo many chemical transformations, usually through an attack on the carbonyl breaking the carbonyl double bond and forming a tetrahedral intermediate. Thiols, alcohols and amines are all known to serve as nucleophiles. Amides are less reactive under physiological conditions than esters.
- Activated acids basic esters with a good leaving group e.g. NHS-activated acids
- amines can react with amines to form amide linkers, under conditions where a normal carboxylic acid would just form a salt.
- SPDP N-succinimidyl 3-(2-pyridyldithio) propionate
- Reductive amination, Michael addition, thio-bromo reactions, amidation using NHS-activated acid, coupling using SPDP reagent, CuAAC and thiol-ene couplings are all suitable to provide benign coupling conditions and high yield of linker formation.
- amine groups shown in Table 3 are for illustrative purposes only and alternative or variant functionalities may of course be employed.
- the amine groups may be positioned on a secondary carbon or the aliphatic chains illustrated may be replaced by aromatic groups.
- the functional end groups of the hyperbranched polymer molecule may be coupled to an anti-coagulant entity by a linker formed through a free radical initiated reaction.
- Radicals may be created for example via heat, photolysis (e.g. Norrish type I and/or Norrish type II reactions), ionization, oxidation, plasma or electrochemical reactions
- radicals such as a e.g. carbon or oxygen radicals are created which may participate in free radical initiated reactions (such as reaction with alkenes).
- the covalent linker comprises a secondary amine linkage.
- the linker may comprise a -NH- group;
- the covalent linker comprises an amide linkage.
- the linker may comprise a -NH-C(O)- group;
- the covalent linker comprises a thioether linkage.
- the covalent linker comprises a 1 ,2,3-triazole linkage.
- thioether linkage refers to a connection between a sulfur and two carbon atoms. This connection is sometimes referred to as "sulfide".
- thiol refers to an -S-H moiety.
- second amine linkage refers to a connection between an NH group and two carbon atoms, i.e. -C-NH-C-.
- amide linkage refers to a connection between two carbon atoms of the type
- the linker between the anti-coagulant entity such as a heparin moiety and a functional end group of the hyperbranched polymer molecule is an unbranched linker.
- the linker can be biodegradable or non-biodegradable but is more suitably non-biodegradable in order that a coated device is non-thrombogenic for a long period of time. Where there is a multiplicity of linkers it is possible for some or all of them to be of a different type.
- all of the linkers are of the same type.
- the covalent connection between the functional end group of the hyperbranched polymer molecule and the anti-coagulant entity is via a linker e.g. as shown in Table 3.
- the linker may be separated by a spacer from either the surface or the anticoagulant moiety or both.
- the purpose of the spacer is usually to significantly increase the separation between the hyperbranched polymer molecule and the anti-coagulant entity i.e. in effect to significantly increase the separation between the surface of the device and the anti-coagulant entity.
- the molecular weight of the spacer may be from 50 to 10 6 Da, typically 100 to 10 6 Da e.g. 100 to 10 4 Da.
- the length of the spacer may for example be from 10 to 10 3 A.
- the spacer is hydrophilic, for example, it may comprise a PEG chain.
- the covalent connection between the functional end group of the hyperbranched polymer molecule and the anti-coagulant entity may be viewed as having three portions - "spacer A" between the functional end group of the hyperbranched polymer molecule and the linker moiety, the linker moiety, and "spacer B" between the linker moiety and the entity.
- the molecular weight of spacer A is between 50 and 10 3 Da.
- the molecular weight of spacer B is between 50 and 10 3 Da.
- spacer A comprises one or more aromatic rings.
- spacer A does not comprise any aromatic rings.
- spacer B comprises one or more aromatic rings.
- spacer B does not comprise any aromatic rings.
- spacer A is hydrophilic.
- spacer B is hydrophilic.
- spacer A comprises a PEG chain.
- spacer B comprises a PEG chain.
- spacers A and B are both hydrophilic, for example they each comprise a PEG chain.
- a PEG chain refers to a polymeric chain obtainable by polymerisation of ethylene oxide, typically of weight between 100 and 10 6 Da.
- the covalent connection may comprise two or more triazole rings.
- the covalent connection may be viewed as having five portions - "spacer A" between the surface and a first linker moiety, the first linker moiety, "spacer B” between the first linker moiety and a second linker moiety, the second linker moiety, and "spacer C” between the second linker moiety and the entity.
- the molecular weight of spacer A is between 50 and 10 3 Da.
- the molecular weight of spacer B is between 100 and 10 6 Da.
- the molecular weight of spacer C is between 50 and 10 3 Da.
- spacer A and/or spacer B and/or spacer C is hydrophilic for example comprising a PEG chain.
- spacer B may comprise a PEG chain.
- spacers may be present they are typically not necessary since it should be noted that the structure of the hyperbranched polymers, by virtue of their size and shape, provides for some separation of the anti-coagulant entity from the surface of the device. In cases where spacers are present, they are for example straight chain spacers of about 10 to 10 3 A.
- a specific merit of having a spacer that comprises a PEG chain (or other hydrophilic polymer) is to provide the device with lubricious properties.
- the spacer can be biodegradable or non-biodegradable but is more suitably non-biodegradable in order that a coated device is non-thrombogenic for a long period of time (i.e. the coated device has preserved non-thromogenic properties).
- linkers shown above in Table 3 can be formed directly by the reaction of a functional end group of a hyperbranched polymer, for example a hyperbranched polyamine with an anti-coagulant entity containing an aldehyde.
- a functional end group of a hyperbranched polymer for example a hyperbranched polyamine with an anti-coagulant entity containing an aldehyde.
- the reductive amination, the Michael addition, the SPDP reaction and the amidation reactions shown in Table 3 require the presence of a primary amine functional end group.
- Hyperbranched molecules such as hyperbranched polyamines e.g.PAMAM dendrimers possess suitable free primary amine groups for use in these linkage forming reactions and therefore do not require further modification.
- the hyperbranched polymer molecule carries multiple free primary amine groups as functional end groups and is, for example, a PAMAM, PPI or PEI hyperbranched polymer molecule.
- Nitrous acid degraded heparin and native heparin bear reactive groups, an aldehyde group and a hemi-acetal function respectively, at their reducing end and thus nitrous acid degraded heparin or native heparin can be reacted with a hyperbranched polymer having free primary amine groups in a reductive amination reaction to form a linker containing a secondary amine group as shown in Table 3 and Scheme 4 above.
- either or both of the anti-coagulant entity and the hyperbranched polymer may be modified to carry a suitable functional group as will be discussed in greater detail below.
- the hyperbranched polymer molecule may be functionalized using techniques known in the art.
- Primary amino groups on a PAMAM dendrimer or similar hyperbranched polymer may be used as points of attachment for a suitable functional group for forming the chosen covalent linkage, for example an alkene, alkyne, thiol, halo or azido group.
- hyperbranched polyamines may be functionalized to bear alkene, alkyne, thiol, halo or azido groups by conventional means e.g. by reacting pendant primary amino groups on the polyamine with an activated carboxylic acid (e.g. an N-hydroxy succinimide derivative of a carboxylic acid) containing an alkene, alkyne, thiol, halo or azido group.
- an activated carboxylic acid e.g. an N-hydroxy succinimide derivative of a carboxylic acid
- a hyperbranched polyamine molecule bearing a number of primary amine groups represented as follows:
- R" is the hyperbranched polyamine residue
- n is an integer from 1 to 8 e.g. 1 to 4;
- the hyperbranched polyamine may be reacted with an activated alkyne-containing group of the formula:
- n is an integer from 1 to 8 e.g. 1 to 4;
- a hyperbranched polymer having free primary amines as functional end groups may be derivatised with a thiol group.
- a hyperbranched polyamine such as a PAMAM dendrimer bearing a number of primary amine groups represented as follows:
- thiol-containing activated carboxylic acid for example a compound of the formula:
- n is an integer from 1 to 8 e.g. 1 to 4;
- Halo groups may be introduced into the hyperbranched polymer molecule in a similar manner.
- An anti-coagulant entity e.g. heparin, carrying an alkene, aldehyde, alkyne, thiol, azo, amine, halide, activated carboxylic acid, maleimide ester or an ⁇ , ⁇ -unsaturated carbonyl group may be made by conventional methods known per se.
- an anti-coagulant entity e.g. heparin, carrying an alkene, aldehyde, alkyne, thiol, azo, amine, halide, activated carboxylic acid, maleimide ester or an ⁇ , ⁇ -unsaturated carbonyl group
- an anti-coagulant entity e.g.
- heparin, carrying an alkyne/alkene group may be made by the reaction of an alkoxyamine of the formula:
- R 1 -0-NH 2 wherein R 1 is an alkyne/alkene-containing group; with an aldehyde or hemi-acetal group on the anti-coagulant entity using conventional techniques known per se, see e.g. Example 3a, 3b and 3c of WO2010/029189.
- This type of reaction proceeds via formation of an oxy-imine function to give a compound of the formula:
- R 1 is as defined above and R' is the residue of the anti-coagulant entity.
- an anti-coagulant entity derivatised with a thiol group may be formed by the reaction of an aldehyde or hemi-acetal group on the anti-coagulant entity with a compound of the formula:
- HS-X-NH 2 where X is a hydrocarbon spacer, for example (CH 2 ) n where n is 1 to 8 e.g. 1 to 4, in which one or more (e.g. 1 or 2) methylene groups are optionally replaced by O; or X comprises a PEG chain containing 1 to 100 (e.g.1 to 50 such as 1 to 10) ethylene glycol units;
- a similar method can be employed for the introduction of an azido group or a halo group such as fluoro, chloro or bromo.
- one reason to modify the hyperbranched polymer is to introduce certain functional groups to permit coupling to the anti-coagulant entity.
- the hyperbranched polymer has certain existing functional end groups e.g. primary amine groups, these may be converted to other functional groups, for example, azide or alkyne groups. All or (more usually) some (e.g. 0.5 to 25%) of the functional groups may be converted for this purpose.
- the device has a surface comprising a layered coating formed of one or more layers.
- the device especially when it is a medical device, may have one or more portions containing void spaces, or pores.
- the pores may be within the device and/or be part of at least one surface of the device.
- An example of a porous medical device is expanded polytetrafluoroethylene (ePTFE).
- ePTFE expanded polytetrafluoroethylene
- the pores may have a coating layer or not. Desirably a portion of the surface (desired to be non-thrombogenic) or the whole of the surface of the device is covered with a coating.
- the surface of a device may have one or many coating layers (e.g. 2 or more, or 3 or 4 or 5 e.g. up to 20 coating layers) and the term "outer coating layer" refers to a coating layer which, in a medical device, is in contact with the tissues of the patient or is in contact with body fluids, or in an analytical or separation device, comes into contact with a substance to be analysed, separated or handled.
- the outer coating layer may be the coating layer on the outer and/or the inner surface of a hollow device or a device of open structure such as a stent.
- a layer which is not the outer coating layer is referred to herein as an "underlayer".
- the outer coating layer comprises a plurality of cationic
- hyperbranched polymer molecules to which are covalently attached via functional end groups one or more anti-coagulant entities.
- the majority, or even all, of the cationic hyperbranched polymer molecules of the outer coating layer will have a plurality of anti-coagulant entities covalently attached thereto via their functional end groups.
- the optimum number of layers will depend on the type of material from which the device is made, and the contemplated use of the surface coating. The number and nature of the layers needed to provide a full coverage of the device surface can be easily determined by those skilled in the art.
- the surface coating may, if desired, be made up layer by layer.
- the coating layer(s) may be formed by adsorbing on the surface of the device a cationic polymer, followed by the application of a solution of an anionic polymer, e.g. an anionic polysaccharide, e.g. dextran sulfate or a functionalized cationic hyperbranched polymer with a net negative charge, to obtain at least one adsorbed layer of the anionic polymer. See
- the surface may comprise a layer of cationic polymer and a layer of anionic polymer e.g. a polysaccharide or a functionalized cationic hyperbranched polymer with a net negative charge.
- the surface coating may comprise one or more coating bilayers of cationic polymer and anionic polymer.
- the innermost layer i.e. the layer applied to the bare device surface, for example a metal, plastic or ceramic surface
- the outer coating layer comprising a plurality of cationic hyperbranched polymer molecules to which are covalently attached one or more anti-coagulant entities via their functional end groups may be applied in one of two ways.
- cationic hyperbranched polymer molecules with a general positive charge may be applied to an anionic polymer on the surface of the device.
- the hyperbranched polymer molecules are then modified to link them to the anti-coagulant entities.
- cationic hyperbranched polymer molecules to which are covalently attached one or more anti-coagulant entities via their functional end groups may be applied to an anionic or cationic polymer on the surface of the device depending on whether the functionalised hyperbranched polymer molecules bear an overall positive or negative charge.
- the cationic hyperbranched polymer molecules may be cross-linked to the polymer surface coating via reactive functional groups. If the cationic hyperbranched polymer is cross-linked to the device surface or to underlying coating layers before reaction with the anti-coagulant entity, it is necessary to ensure that a sufficient number of amino groups (or other reactive groups introduced) remain available to be able to link the desired amount of anti- coagulant entity to the outer coating layer. Alternatively, the cationic hyperbranched polymer molecules can be reacted with the anti-coagulant entities before application to the surface of the device or to a coating layer and then cross-linked. Typically there is no cross-linking directly between the anti-coagulant entity and the surface coating. A range of cationic polymers may be used for the underlayers. An exemplary cationic polymer is a polyamine (e.g. that described in EP 0086187 Larsson and Golander). Such polymers may be a straight chain but is more usually a branched chain polymer or alternatively a
- hyperbranched polymer optionally cross-linked.
- one or more (e.g. all of) the cationic polymer layers other than the outer coating layer may comprise (e.g. be formed of) cationic hyperbranched polymer molecules, which are the same as or similar to those used in the outer coating layer. Optionally these may also be cross-linked.
- the coating procedure may be performed essentially as described in EP-B-0495820 and in this case it is only the outer coating layer which comprises the anti-coagulant entity.
- EP-B-0495820 may however be modified so that the outer layer is the anionic polymer which is then coupled, as described below, with a cationic hyperbranched polymer to which is attached one or more anti-coagulant entities (but that still retains a net positive charge) or is coupled with a cationic hyperbranched polymer with functional end group(s) capable of reacting with functional groups on an anti-coagulant entity to form a covalent linker moiety as described above.
- a device wherein one or more of the layers of the layered coating other than the outer coating layer comprises cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80: 1 (e.g. at least 100:1) and (iv) functional end groups which are optionally derivatised e.g. with one or more anti-coagulant entities.
- underlayers when underlayers comprise cationic polymers they may comprise cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80:1 (e.g. at least 100: 1) and (iv) functional end groups.
- these cationic hyperbranched polymer molecules may be the same as those used in the outer coating layer (but without the anti-coagulant entity attached) or they may be different hyperbranched polymer molecules.
- exemplary cationic hyperbranched polymer molecules include those described elsewhere herein in relation to those cationic hyperbranched polymer molecules that may be used in preparation of the outer coating layer.
- all the underlayers which comprise cationic polymers may comprise cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80: 1 (e.g. at least 100: 1); and (iv) functional end groups.
- the anionic polymer may also be a functionalized cationic hyperbranched polymer with a net negative charge.
- underlayers when underlayers comprise anionic polymers they may comprise cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80: 1 (e.g. at least 100: 1) and (iv) functional end groups, whereby one or more of said functional end groups have an anionic anti-coagulant entity covalently attached thereto thereby conferring on the molecules a net negative charge.
- all the underlayers which comprise anionic polymers may comprise cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80: 1 (e.g. at least 100: 1) and (iv) functional end groups, whereby one or more of said functional end groups have an anionic anticoagulant entity covalently attached thereto thereby conferring on the molecules a net negative charge.
- the layers of the coating on the surface of the device are all either (a) cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80: 1 (e.g.
- One advantage of this is that the number of different components of the layers of the coating is minimized.
- the surface of the device Prior to applying the first coating layer (i.e. the innermost layer), the surface of the device may be cleaned to improve adhesion and surface coverage.
- Suitable cleaning agents include solvents as ethanol or isopropanol (IPA), solutions with high pH like solutions comprising a mixture of an alcohol and an aqueous solution of a hydroxide compound (e.g.
- TMAH tetramethyl ammonium hydroxide
- basic Piranha ammonia and hydrogen peroxide
- acidic Piranha a mixture of sulfuric acid and hydrogen peroxide
- oxidizing agents including combinations of sulfuric acid and potassium permanganate or different types of peroxysulfuric acid or peroxydisulfuric acid solutions (also as ammonium, sodium, and potassium salts).
- an aspect of the invention is a device having a surface coating wherein the surface coating comprises one or more coating bilayers of cationic polymer and anionic polymer, wherein the outer coating layer of the coating comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80: 1 (e.g. at least 100: 1) and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto.
- the heparin moiety or other anti-coagulant entity may be attached to the hyperbranched polymer molecules either before or after the hyperbranched polymer molecules are applied to the surface of the device.
- the surface of the device to which the outer coating layer is applied may optionally contain one or more underlayers. See Figure 7. Therefore, in a further aspect of the invention there is provided a process for the manufacture of a device as described above, the process comprising, in any order:
- hyperbranched polymer molecules i. reacting a plurality of functional end groups of hyperbranched polymer molecules with anti-coagulant entities such that each hyperbranched polymer molecule is covalently linked to a plurality of anti-coagulant entities; and ii. attaching the hyperbranched polymer molecules to the surface of a device.
- the anti-coagulant entities are attached to hyperbranched polymer molecule via a covalent linkage and it may, in some cases, be necessary to carry out an additional step of modifying the hyperbranched polymer molecules and/or the anti-coagulant entity before step (i) in order to introduce suitable functional groups for forming a covalent linkage between the hyperbranched polymer molecules and the anti-coagulant entity.
- linker may optionally be separated from the surface and/or the anti-coagulant moiety by a spacer.
- process may optionally involve the modification of the surface and/or the anti-coagulant moiety by provision of a spacer.
- step (i) the process of attaching the anti-coagulant entities to the hyperbranched polymer molecules may be carried out in solution under appropriate reaction conditions with suitable solvents being, for example THF, DCM, DMF, DMSO, I PA, methanol, ethanol and water including mixtures thereof.
- suitable solvents being, for example THF, DCM, DMF, DMSO, I PA, methanol, ethanol and water including mixtures thereof.
- the outer coating layer of the device will usually be brought into contact with a solution of the anticoagulant entity under the appropriate reaction conditions.
- Suitable solvents for the anti- coagulant entity are, for example, IPA, ethanol, THF, DMF, DMSO, DCM and especially water including mixtures thereof.
- two or more hyperbranched polymer molecules may be aggregated by cross-linking.
- the process above may further comprise the additional step of cross-linking two or more hyperbranched polymer molecules to one another.
- the two or more hyperbranched polymer molecules may be aggregated by cross-linking before or after the hyperbranched polymer molecules are functionalized with the one or more anti-coagulant entities.
- the order in which cross-linking is performed may depend on the device e.g. the geometry of the device.
- the cross-linking is performed after the functionalisation.
- this cross- linking step may take place either before or after the attachment of the hyperbranched polymer molecules to the surface of the device.
- the process may also include the step of cross-linking one or more hyperbranched polymer molecules to the surface of the device.
- hyperbranched polymer molecules to which are attached one or more anti-coagulant entities on the outer coating layer may also be cross linked to a cationic or anionic polymer of the layer underneath the other coating layer.
- This cross-linking step may be part of step (ii) above or, alternatively the cross-linking step may be carried out after step (ii) in order to strengthen the adhesion of the hyperbranched polymer molecules to the surface of the device and enhance the stability of the coating.
- any required cross-linking either between two or more hyperbranched polymer molecules or between hyperbranched polymer molecules and the surface, is carried out before derivatisation, it is necessary to ensure that sufficient free functional groups remain on the hyperbranched molecule to allow attachment of a suitable number of anti-coagulant entities.
- derivatisation is carried out first, then the degree of derivatisation must be such that free functional groups remain for any cross-linking that is required.
- step (i) is carried out before step (ii) since it is easier to control the amount of anti-coagulant entity which is attached to the hyperbranched polymer molecules and, in addition, wastage of anti-coagulant entity is minimized, particularly when the reaction is carried out in solution as described above.
- Another aspect of the invention is a non-thrombogenic device which is obtainable by a process comprising:
- cationic hyperbranched polymer molecules comprising cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da and bearing functional end groups and (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80: 1 (e.g. at least 100: 1);
- Another aspect of the invention is a non-thrombogenic device which is obtainable by a process comprising:
- polymer molecules characterized by having (i) a core moiety of molecular weight 14-
- Another aspect of the invention is a non-thrombogenic device which is obtainable by a process comprising:
- polymer molecules characterized by having (i) a core moiety of molecular weight 14- 1 ,000 Da (ii) a total molecular weight of 1 ,500 to 1 ,000,000 Da and (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80: 1 (e.g. at least 100: 1) and bearing one or more negatively charged anti-coagulant entities such as heparin moieties and wherein said functionalized hyperbranched polymer has a net positive charge.
- the device is treated to present a surface comprising an anionic polymer for example a polysaccharide such as dextran sulfate, derivatives thereof or a functionalized cationic hyperbranched polymer with a net negative charge.
- hyperbranched polymer molecules of the outer coating layer may optionally be cross-linked to other hyperbranched polymer molecules of the outer coating layer or may be cross-linked to molecules (e.g. hyperbranched polymer molecules) of an underlayer.
- Polymer molecules in underlayers may optionally be cross linked.
- cross linking agents that may be used for these purposes will be chosen according to the coupling chemistry required. Any di, tri, or multi functional cross-linker may, in principle, be used such as functionalised PEGs and Jeffamines. For cross linking of amines it would be suitable to use di-functional aldehydes such as crotonaldehyde or glutaraldehyde. In some cases epichlorohydrin may be useful.
- Cross linking is capable of creating a covalent bond between a functional end group of the hyperbranched polymer molecule of the outer coating layer and a functional end group of another hyperbranched polymer molecule of the outer coating layer or a molecule (e.g. a hyperbranched polymer molecule or a cationic or anionic polymer molecule) of an underlayer.
- Such cross-linking suitably does not involve the anti-coagulant entity.
- the anticoagulant entity has a covalent connection only to one hyperbranched polymer molecule and not to any other molecule.
- the cross linking of one hyperbranched polymer molecule to another hyperbranched polymer molecule involves use of functional end groups on the hyperbranched polymer molecule which are not involved in linkage to the anti-coagulant entity.
- said functional groups used in cross-linking are formed by refunctionalisation of the original functional end groups of the hyperbranched polymer molecule.
- the device may be any device to which it is desirable to attach anti-coagulant entities, for example a medical device, an analytical device or a separation device.
- the term “medical device” refers to implantable or non-implantable devices but more usually to implantable medical devices.
- implantable medical devices which may be permanent or temporary implantable medical devices include catheters, stents including bifurcated stents, balloon expandable stents, self- expanding stents, stent-grafts including bifurcated stent-grafts, grafts including vascular grafts, bifurcated grafts, artificial blood vessels, blood indwelling monitoring devices, artificial heart valves, pacemaker electrodes, guidewires, cardiac leads, cardiopulmonary bypass circuits, cannulae, plugs, drug delivery devices, balloons, tissue patch devices and blood pumps.
- non-implantable medical devices are extracorporeal devices, e.g. extracorporeal blood treatment devices, and transfusion devices.
- Devices may have neurological, peripheral, cardiac, orthopedal, dermal and gynecological application, inter alia.
- a medical device may have one or many coating layers and the term "outer coating layer" refers to a coating layer which, when the device is implanted in a patient or is in use, is in contact with the tissues of the patient or is in contact with body fluids e.g blood.
- the outer coating layer may be the coating layer on the outer and/or the inner surface of a hollow device or a device of open structure such as a stent.
- An analytical device may be, for example, a solid support for carrying out an analytical process such as chromatography or an immunological assay, reactive chemistry or catalysis .
- a separation device may be, for example, a solid support for carrying out a separation process such as protein purification, affinity chromatography or ion exchange. Examples of such devices include filters and columns etc.
- an analytical or separation device may also have many coating layers and the term "outer coating layer" refers to a coating layer which comes into contact with a substance to be analysed, separated or handled.
- one or more additional entities may be attached to the hyperbranched polymer in addition to the anti-coagulant entity.
- the additional entities may comprise one or more PEG chains.
- PEG chain refers to a polymeric chain obtainable by polymerisation of ethylene oxide, typically of weight between 10 2 and 10 6 Da.
- the coating of the device may comprise alternate layers of a cationic polymer and an anionic polymer.
- the cationic polymer may be a straight chain polymer but is more usually a branched chain polymer, a hyperbranched polymer or a polymer comprising a plurality of (cationic) hyperbranched polymer molecules, wherein, in the outer coating layer, there are covalently attached to said hyperbranched polymer molecules one or more anti-coagulant entities via their functional end groups.
- one or more layers of the coating may be formed from the same or similar hyperbranched polymer molecules as the outer layer.
- the device may comprise or be formed of a metal or a synthetic or naturally occurring organic or inorganic polymer or a ceramic material, inter alia.
- polyethylene polypropylene
- polyacrylate polycarbonate
- polysaccharide polyamide, polyurethane (PU), polyvinylchloride (PVC), polyetheretherketone (PEEK), cellulose, silicone or rubber (polyisoprene)
- PVC polyvinylchloride
- PEEK polyetheretherketone
- cellulose silicone or rubber
- suitable substrate materials include fluoropolymers, e.g expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), fluorinated ethylene-propylene (FEP), perfluorocarbon copolymers, e.g.
- fluoropolymers e.g expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), fluorinated ethylene-propylene (FEP), perfluorocarbon copolymers, e.g.
- TFE/PAVE tetrafluoroethylene perfluoroalkylvinyl ether copolymers, copolymers of tetrafluoroethylene (TFE) and perfluoromethyl vinyl ether (PMVE), and combinations of the above with and without crosslinking between the polymer chains.
- Suitable metals include nickel titanium alloy (Nitinol), stainless steel, titanium, cobalt chromium, gold and platinum. Nitinol and stainless steel are preferred. Titanium is also preferred.
- suitable metals include metallic materials and alloys such as cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, cobalt chrome alloy L- 605, MP35N, MP20N , tantalum, nickel-titanium alloy, nitinol, platinum-iridium alloy, gold, magnesium, and combinations thereof.
- ELGILOY cobalt chromium alloy
- stainless steel 316L
- high nitrogen stainless steel high nitrogen stainless steel
- cobalt chrome alloy L- 605 cobalt chrome alloy L- 605
- MP35N MP35N
- MP20N tantalum
- nickel-titanium alloy nickel-titanium alloy
- nitinol platinum-iridium alloy
- gold magnesium, and combinations thereof.
- the coated surface to which the anti-coagulant entity e.g. heparin or other heparin moiety
- the anti-coagulant entity e.g. heparin or other heparin moiety
- EO ethylene oxide
- Sterilization may be carried out by means well known to those skilled in the art.
- the preferred method of sterilization is using ethylene oxide gas.
- other methods such as radiation, e.g. e-beam or gamma radiation, may be used where such radiation will not degrade the object or the coating or both.
- a preferred embodiment of the present invention relates to a coated medical device for implantation e.g. permanent implantation, or other placement, at an anatomical site.
- Other preferred embodiments include temporary use devices such as catheters and extracorporeal circuits.
- Examples are sterile (e.g. sterilized) medical devices for placement inside an anatomical structure delimiting a void space, or lumen, to reinforce the anatomical structure or maintain the void space.
- the attached anti-coagulant entity e.g. heparin or other heparin moiety, does not elute to any substantial extent and remains with the device. For example, after 15 hour rinse with NaCI (0.15 M) prior to testing the retained AT binding capacity remains adequate (e.g.
- the reduction in platelet count of the blood after the test is substantially lower for the blood exposed to the coated surface according to the invention than that of an uncoated control (e.g. the reduction in platelet count after the test for the blood exposed to the coated surface is less than 20%, preferably less than 15% and more preferably less than 10%).
- non-thrombogenic character of devices according to the present invention may be tested by a number of methods.
- non-thrombogenic character may be associated with having a high antithrombin binding capacity, especially as compared with devices having untreated surfaces.
- the surface of the device e.g. the medical device to have an
- antithrombin (AT) binding capacity of at least 1 (e.g. at least 5) picomoles AT per square centimeter (pmol/cm 2 ) of surface.
- the AT binding capacity is at least 6 pmol/cm 2 , at least 7 pmol/cm 2 , at least 8 pmol/cm 2 , at least 9 pmol/cm 2 , or at least 10 pmol/cm 2 of surface.
- the AT binding capacity is at least 100 pmol/cm 2 of surface. AT binding capacity can be measured by methods known in the art, e.g. those described in Pasche., et al., in "Binding of antithrombin to immobilized heparin under varying flow
- the thrombogenicity of an uncoated control surface is indicated by a reduction in platelet count of the exposed blood, measured after the test.
- the non-thrombogenicity of a surface prepared according to the method described herein is indicated by a reduction in the platelet count of the blood to a substantially lower degree (e.g. the reduction in platelet count after the test for the blood exposed to the coated surface is less than 20%, preferably less than 15% and more preferably less than 10%).
- the amount of the anti-coagulant entity bound to a particular surface area can easily be controlled and adjusted by choosing particular sizes and amounts of hyperbranched molecule for the coating.
- the distribution of the anti-coagulant entity on the surface can be determined by conventional staining techniques which are known perse, e.g. the distribution of heparin can be determined using toluidine blue.
- the layered coating of the device may comprise one or more beneficial agents besides the anti-coagulant entities.
- beneficial agents include drug molecules and lubricious agents.
- the beneficial agent may be introduced to the underlayers or to the outer coating layer.
- Beneficial agents may be attached to the coating by a covalent linkage, which may be degradable to allow migration (i.e. elution) of the beneficial agent from the polymer surface or it may not be degradable if long lasting action is required. Alternatively, they may be adsorbed onto or incorporated within the coating surface (e.g. within any of its layers) without covalent linkage.
- the linkage between the drug molecules and the coating is a degradable covalent linkage to allow migration (i.e. elution) of the drug molecules from the polymer surface.
- the drug may be adsorbed onto or incorporated within the coating surface without covalent linkage.
- the drugs may also be incorporated into the voids of the hyperbranched polymer prior to usage in the coating build up. Hydrophobic drugs may, in particular, be incorporated into the hydrophobic voids of the hyperbranched polymer.
- drugs that may be used in this embodiment include drugs that prevent restenosis such as anti-angiogenic or anti-proliferative drugs such as paclitaxel and sirolimus.
- Another application is the use of elutable heparin or other anti-coagulant entities.
- an antimicrobial drug may be attached to the coating in addition to the anti-coagulant entity.
- beneficial agents When beneficial agents are covalently attached to a molecule of the coating, this may be achieved by covalently attaching beneficial agent(s) to cationic hyperbranched polymer molecules as described herein through functional end groups which are not involved in attachment to the anti-coagulant entity. These functional end groups may be the original functionality (e.g. primary amine) or the functionality may be changed prior to attachment to the beneficial agent.
- the coupling of beneficial agents may be conducted in a similar manner, as earlier described, as for the coupling of anti-coagulant entities.
- Beneficial agents may be coupled to hyperbranched polymers of the invention before coupling of anti-coagulant entities, however more usually they will be coupled afterwards.
- the layered coating of the device may optionally comprise at least one beneficial agent selected from: paclitaxel, a taxane or other paclitaxel analogue; estrogen or estrogen derivatives; heparin or another thrombin inhibitor, hirudin, hirulog, apyrase, argatroban, D-phenylalanyl-L-poly-L-arginyl chloromethyl ketone, or another antithrombogenic agent, or mixtures thereof; urokinase, streptokinase, a tissue plasminogen activator, or another thrombolytic agent, or mixtures thereof; a fibrinolytic agent; a vasospasm inhibitor; a calcium channel blocker, a nitrate, nitric oxide, a nitric oxide promoter or another vasodilator;; aspirin, ticlopidine or another antiplatelet agent; vascular endothelial growth factor
- alphatocopherol superoxide dismutase, deferoxyamine, a 21-aminosteroid (lasaroid) or another free radical scavenger, iron chelator or antioxidant; angiopeptin; a 14 C-, 3 H-, 131 1-, 32 P or 36 S-radiolabelled form or other radiolabeled form of any of the foregoing; or a mixture of any of these.
- lubricious agents including polymers such as hydrophilic or hydrogel polymers containing polar or charged functional groups which render them soluble in water. These agents incorporate polar groups that have an affinity to water molecules in solution, and are broadly classified as hydrogels. It may also be appropriate to attach lubricious agents to the coating in addition to the anti-coagulant entity.
- the linkage between the lubricious agents and the outer coating layer may be a covalent linkage.
- the lubricious agent may be adsorbed ionically or physically onto or incorporated within the coating surface without covalent linkage.
- lubricous agents are, but are not limited to, hyaluronic acid, hyaluronic acid derivatives, poly-N-vinylpyrrolidone, poly-N-vinylpyrrolidone derivatives, polyethylene oxide, polyethylene oxide derivatives, polyethylene glycol, polyethylene glycol derivatives, polyvinylalcohol, polyvinylalcohol derivatives, polyacrylic acid, polyacrylic acid derivatives, silicon, silicon derivatives, polysaccharide, polysaccharide derivatives, Sulfonated polystyrene, Sulfonated polystyrene derivatives, polyallylamine, polyallylamine derivatives,
- beneficial agents may, for example, be covalently attached to hyperbranched polymer molecules in the outer coating layer.
- beneficial agent(s) may be incorporated into which ever surface is appropriate to achieve the beneficial effect.
- the beneficial agent(s) may be incorporated into the surface of a tubular device on either or both of the luminal and abluminal sides.
- the different beneficial agents may be incorporated into the same surface, or part of the surface, or different surfaces or parts of the surface.
- the length of the covalent connection (linker(s) and spacer(s)) between the entity and the hyperbranched polymer may be controlled;
- -Full length heparin may be used thus avoiding the cleavage of heparin and thus optimizing the use of heparin raw material;
- -Use of full-length heparin or heparin linked via a spacer may improve the bioactivity of the bound heparin
- -A uniform coating may be obtained which will mask the intrinsic properties, for example lower the thromogenic properties, of a device irrespective of the material of its manufacture;
- -A coating may be obtained which is comparatively smooth and/or lubricious
- -A coating may be prepared in which a pre-prepared conjugate with covalently bound heparin may be used in the coating build up process;
- -A coating according to the present invention may reduce the need for systemic heparin, and reduce the likelihood of contact activation; -A medical device having a combination of lubricity and thromboresistance can be obtained which may be beneficial in certain applications e.g. neuro vascular applications;
- -A medical device having a combination of drug eluting properties and thromboresistance can be obtained which may be beneficial in certain applications e.g. drug eluting stents and drug eluting balloons;
- -A medical device having a combination of anti-inflammatory properties and thromboresistance can be obtained which may be beneficial in certain applications e.g. cardiovascular
- Lupasol samples were purchased from BASF.
- Lupasol ® WF ethylene diamine core
- Dextrane sulfate was purchased from pK Chemicals A/S (PKC) and PAMAM dendrimers (ethylene diamine core) were purchased from Sigma Aldrich and Dendritech.
- PAMAM-G6.0-NH 2 is a PAMAM dendrimer (6 th generation) with molecular weight of approximately 60 kDa.
- PAMAM-G8.0-NH 2 is a PAMAM dendrimer (8 th generation) with molecular weight of approximately 230 kDa.
- PPI G5 dendrimer (butane-1 , 4-diamine core) was purchased from Aldrich.
- PPI G5 is a dendrimer (5 th generation) with a molecular weight of approximately 7 kDa.
- the polyamine Epomin P- 1050 (ethylene diamine core) was purchased from Nippon Shokubai and has an average molecular weight of 70 kDa.
- the polyamine G-35 was purchased from Wuhan Bright Chemicals and has an average molecular weight of 70 kDa. All polyamine stock solutions were 5wt% in water. The dextran sulfate stock solution was 6wt% in water. The solutions were subsequently diluted as appropriate before use. A water rinse was performed in between each process step as appropriate.
- Example 1.1 Preparation of underlayer comprising Lupasol ® SN
- a PVC surface was pretreated using the method described by Larm et al in EP-B-0086186 and EP-495820 (layer-by-layer; polyelectrolyte charge interactions) ending with a layer of sulfated polysaccharide.
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® SN, 5 wt% in water) and negatively charged sulfated polysaccharide (dextran sulfate, 6 wt% in water).
- the polyamine was crosslinked with a difunctional aldehyde (crotonaldehyde). Every pair of polyamine and sulfated polysaccharide is called one bilayer.
- the PVC surface was primed with 3 bilayers ending with the sulfated polysaccharide.
- Example 1.2 Preparation of underlayer comprising Lupasol ® WF A PVC surface was pretreated using the method described by Larm et al in EP-B-0086186 and EP-495820 (layer-by-layer; polyelectrolyte charge interactions) ending with a layer of sulfated polysaccharide.
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® WF, 5 wt% in water) and negatively charged sulfated polysaccharide (dextran sulfate, 6 wt% in water).
- the polyamine was crosslinked with a difunctional aldehyde
- Example 1.3 Preparation of underlayer comprising PAMAM-G6.0-NH 2 dendrimer Quartz Crystal Microbalance (QCM) crystals covered with gold (QSX 301 , Q-Sense) were coated according to Example 1.1 using 5wt% in MeOH PAMAM-G6.0-NH 2 (1 ml_/L) to obtain a 3 bilayer coating consisting of alternatively layers of PAMAM-G6.0-NH 2 and a sulfated polysaccharide (6 wt% in water).
- the polyamine was crosslinked with a difunctional aldehyde (crotonaldehyde). A 2 min water rinse is conducted in between each adsorption step.
- the gold surface was primed with 3 bilayers ending with the sulfated polysaccharide.
- Example 1.4 Preparation of underlayer comprising Lupasol ® SK and heparin
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® SK, 5 wt% in water, 10 minutes) and negatively charged PAMAM-heparin conjugate (400 mg/L, from Example 5.2, 20 minutes).
- the polyamine was crosslinked with a difunctional aldehyde (crotonaldehyde). Every pair of polyamine and PAMAM-heparin conjugate is called one bilayer.
- the PVC surface was primed with 3 bilayers ending with the PAMAM-heparin conjugate from Example 5.2.
- Example 1.5 Preparation of underlayer using Lupasol ® WF and heparin functionalized PAMAM-G6.O-NH2 dendrimer
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® WF, 5 wt% in water, 10 minutes) and negatively charged PAMAM-heparin conjugate (400 mg/L, from Example 5.2, 20 minutes).
- the polyamine was crosslinked with a difunctional aldehyde (crotonaldehyde). Every pair of polyamine and PAMAM-heparin conjugate is called one bilayer.
- the PVC surface was primed with 3 bilayers ending with the PAMAM-heparin conjugate from Example 5.2.
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (G- 35, 5 wt% in water) and negatively charged sulfated polysaccharide (dextran sulfate, 6 wt% in water).
- the polyamine is crosslinked with a difunctional aldehyde (crotonaldehyde). Every pair of polyamine and sulfated polysaccharide is called one bilayer.
- the PVC surface was primed with 3 bilayers ending with the sulfated polysaccharide.
- Example 1.7 Preparation of underlying layers using Lupasol® SK
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® SK, 5 wt% in water) and negatively charged sulfated polysaccharide (dextran sulfate, 6 wt% in water).
- the polyamine was crosslinked with a difunctional aldehyde (crotonaldehyde). Every pair of polyamine and sulfated polysaccharide is called one bilayer.
- the PVC surface was primed with 3 bilayers ending with the sulfated polysaccharide.
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Epomin P-1050, 5 wt% in water) and negatively charged sulfated polysaccharide (dextran sulfate, 6 wt% in water).
- the polyamine was crosslinked with a difunctional aldehyde
- Example 2 Preparation of a non-thrombogenic coating comprising a hyperbranched polymer in the outer coating layer
- Example 2.1 Preparation of outer coating layer comprising Lupasol ® WF on underlayer comprising Lupasol ® SN
- a solution of Lupasol ® WF (5 wt%) was allowed to adsorb for 10 minutes to the prefabricated coating surface from Example 1.1 followed by a 1 hour coupling step of nitrous acid degraded heparin (325 mg/L), from Example 4.1 , using a reducing agent (sodium cyanoborohydride, 2.5 wt% in water).
- a reducing agent sodium cyanoborohydride, 2.5 wt% in water.
- a 2 min water rinse is conducted in between each adsorption step.
- the fabricated non-thrombogenic coating was treated with a borate/phosphate solution to remove any potential ionically bound heparin prior to evaluation of its non-thrombogenic properties.
- Example 2.2 Preparation of outer coating layer comprising Lupasol ® WF on underlayer comprising Lupasol ® WF
- Example 2.3 Preparation of outer coating layer comprising PAMAM-G6.0-NH 2 dendrimer on underlayer comprising Lupasol ® SN
- a solution of PAMAM-G6.0-NH 2 (5 wt%) was allowed to adsorb for 10 minutes to the prefabricated coating surface from Example 1.1 followed by a 1 hour coupling step of nitrous acid degraded heparin (325 mg/L), from Example 4.1 , using a reducing agent (sodium cyanoborohydride, 2.5 wt% in water). A 2 min water rinse is conducted in between each adsorption step.
- the fabricated non-thrombogenic coating was treated with a borate/phosphate solution to remove any potential ionically bound heparin prior to evaluation of its non- thrombogenic properties.
- Example 2.4 Preparation of outer coating layer comprising PAMAM-G6.0-NH 2 dendrimer on underlayer comprising PAMAM-G6.0-NH 2 dendrimer
- a solution of PAMAM-G6.0-NH 2 (5 wt%) was allowed to adsorb for 30 minutes to the prefabricated coating surface from Example 1.3 followed by a 1 hour coupling step of nitrous acid degraded heparin (325 mg/L), from Example 4.1 , using a reducing agent (sodium cyanoborohydride, 2.5 wt% in water).
- a reducing agent sodium cyanoborohydride, 2.5 wt% in water.
- a 2 min water rinse is conducted in between each adsorption step.
- the fabricated non-thrombogenic coating was treated with a borate/phosphate solution to remove any potential ionically bound heparin prior to evaluation of its non- thrombogenic properties.
- Example 2.5 Preparation of outer coating layer comprising G-35 on underlayer comprising Lupasol ® SN
- Example 2.7 Preparation of outer coating layer comprising 10 wt% Lupasol ® WF and 90 wt % Lupasol ® SN on underlayer comprising Lupasol ® SN
- a mixture of 10 wt% Lupasol ® WF (5 wt% solution) and 90 wt % Lupasol ® SN (5 wt% solution) was allowed to adsorb for 10 minutes to the prefabricated surface from Example 1.1 followed by a 1 hour coupling step of nitrous acid degraded heparin (325 mg/L), from Example 4.1 , using a reducing agent (sodium cyanoborohydride, 2.5 wt% in water). A 2 min water rinse is conducted in between each adsorption step.
- the fabricated non-thrombogenic coating was treated with a borate/phosphate solution to remove any potential ionically bound heparin prior to evaluation of its non-thrombogenic properties.
- Example 2.8 Preparation of outer coating layer comprising 10 wt% Lupasol ® WF and 90 wt % Lupasol ® SK on underlayer comprising Lupasol ® SK
- a mixture of 10 wt% Lupasol ® WF (5 wt% solution) and 90 wt % Lupasol ® SK (5 wt% solution) was allowed to adsorb for 10 minutes to the prefabricated coating surface from Example 1.7 followed by a 1 hour coupling step of nitrous acid degraded heparin (325 mg/L), from Example 4.1 , using a reducing agent (sodium cyanoborohydride, 2.5 wt% in water). A 2 min water rinse is conducted in between each adsorption step.
- the fabricated non-thrombogenic coating was treated with a borate/phosphate solution to remove any potential ionically bound heparin prior to evaluation of its non-thrombogenic properties.
- Example 2.9 Preparation of outer coating layer comprising Lupasol ® WF on underlayer comprising Lupasol ® SK
- a solution of Lupasol ® WF (5 wt%) was allowed to adsorb for 10 minutes to the prefabricated coating surface from Example 1.7 followed by a 1 hour coupling step of nitrous acid degraded heparin (325 mg/L), from Example 4.1 , using a reducing agent (sodium cyanoborohydride, 2.5 wt% in water).
- a reducing agent sodium cyanoborohydride, 2.5 wt% in water.
- a 2 min water rinse is conducted in between each adsorption step.
- the fabricated non-thrombogenic coating was treated with a borate/phosphate solution to remove any potential ionically bound heparin prior to evaluation of its non-thrombogenic properties.
- Example 2.10 Preparation of outer coating layer comprising Epomin P-1050 on underlayer comprising Lupasol ® SN
- Epomin P-1050 5 wt% was allowed to adsorb for 10 minutes to the prefabricated coating surface from Example 1.1 followed by a 1 hour coupling step of nitrous acid degraded heparin (325 mg/L), from Example 4.1 , using a reducing agent (sodium cyanoborohydride, 2.5 wt% in water). A 2 min water rinse is conducted in between each adsorption step.
- the fabricated non-thrombogenic coating was treated with a borate/phosphate solution to remove any potential ionically bound heparin prior to evaluation of its non-thrombogenic properties.
- Example 2.11 Preparation of outer coating layer comprising heparinized Lupasol® WF on underlayer comprising Lupasol® SN
- Lupasol® WF (5 wt% in water) was allowed to adsorb onto an underlaying layer described essentially as in Example 1.1 yielding a positively charged surface.
- Na heparin (325 mg/L) was subsequently coupled to the positively charged layer using 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (23.35 mg/L) at room temperature for 60 minutes followed by a
- borate/phosphate rinse to remove any loosely bound heparin prior to evaluation of the non- thrombogenic effect of the coating.
- Example 2.12 Preparation of outer coating layer comprising apyrase functionalized Lupasol® WF on underlayer comprising Lupasol® SN
- Apyrase, ⁇ 200 units/mg protein, derived from potato was purchased from Sigma-Aldrich.
- the carboxylic content in apyrase was calculated to be approximately 90 moles of COOH per 1 mole of apyrase based on an amino acid analysis performed by Aminosyraanalyscentralen, Sweden.
- Carboxylic groups in non-thrombogenic agents, such as apyrase may be used to link them to an amine containing hyperbranched polymer using EDC, or EDC like, reagents essentially as described in Example 2.1 1.
- Example 3 Preparation of a non-thrombogenic coating comprising a pre-prepared heparin functionalized hyperbranched polymer in the outer coating layer
- Example 3.1 Preparation of outer coating layer comprising heparin functionalized PAMAM-G6.O-NH2 dendrimer on underlayer comprising Lupasol ® SN
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® SN, 5 wt% in water) and negatively charged sulfated polysaccharide (dextran sulfate, 6 wt% in water).
- the polyamine was crosslinked with a difunctional aldehyde (crotonaldehyde). Every pair of polyamine and sulfated polysaccharide is called one bilayer.
- the PVC surface was primed with 3 bilayers and one layer of Lupasol ® SN.
- Heparin functionalized PAMAM- G6.O-NH2 dendrimer 150 mg/L from Example 5.2 was deposited onto the positively charged Lupasol ® SN coating for 1 hour followed by a borate/phosphate rinse to remove any loosely bound heparin conjugate prior to evaluation of the non-thrombogenic effect of the coating.
- Example 3.2 Preparation of outer coating layer comprising heparin functionalized PAMAM-G6.O-NH2 dendrimer on underlayer comprising Lupasol ® SK, Lupasol ® WF and heparin functionalized PAMAM-G6.0-NH 2 dendrimer
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® SK, 5 wt% in water) and negatively charged PAMAM-heparin conjugate (400 mg/L, from Example 5.2).
- the polyamine was crosslinked with a difunctional aldehyde
- Example 3.3 Preparation of outer coating layer comprising heparin functionalized PAMAM-G6.O-NH2 dendrimer on underlayer comprising Lupasol ® WF and heparin functionalized PAMAM-G6.0-NH 2 dendrimer
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® WF, 5 wt% in water) and negatively charged PAMAM-heparin conjugate (400 mg/L, from Example 5.2).
- the polyamine was crosslinked with a difunctional aldehyde
- Example 3.4 Preparation of outer coating layer comprising heparin functionalized PAMAM-G6.O-NH2 dendrimer on underlayer comprising Lupasol ® SN
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® SN, 5 wt% in water) and negatively charged sulfated polysaccharide (dextran sulfate, 6 wt% in water).
- the polyamine was crosslinked with a difunctional aldehyde (crotonaldehyde). Every pair of polyamine and sulfated polysaccharide is called one bilayer.
- the PVC surface was primed with 3 bilayers and one layer of Lupasol ® SN.
- Heparin functionalized PAMAM- G6.O-NH2 dendrimer (425 mg/L) from Example 5.2 was deposited onto the positively charged Lupasol SN coating for 1 hour followed by a borate/phosphate rinse to remove any loosely bound heparin conjugate prior to evaluation of the non-thrombogenic effect of the coating.
- Example 3.5 Preparation of outer coating layer comprising heparin functionalized Lupasol ® WF on underlayer comprising Lupasol ® SN
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® SN, 5 wt% in water) and negatively charged sulfated polysaccharide (dextran sulfate, 6 wt% in water).
- the polyamine was crosslinked with a difunctional aldehyde (crotonaldehyde). Every pair of polyamine and sulfated polysaccharide is called one bilayer.
- the PVC surface was primed with 3 bilayers and one layer of Lupasol ® SN.
- Heparin functionalized Lupasol ® WF (425 mg/L) from Example 5.3 was deposited onto the positively charged Lupasol ® SN coating for 1 hour followed by a borate/phosphate rinse to remove any loosely bound heparin conjugate prior to evaluation of the non-thrombogenic effect of the coating.
- Example 3.6 Preparation of outer coating layer comprising heparin functionalized PAMAM-G8.O-NH 2 dendrimer on underlayer comprising Lupasol ® SN
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® SN, 5 wt% in water) and negatively charged sulfated polysaccharide (dextran sulfate, 6 wt% in water).
- the polyamine was crosslinked with a difunctional aldehyde (crotonaldehyde). Every pair of polyamine and sulfated polysaccharide is called one bilayer.
- the PVC surface was primed with 3 bilayers and one layer of Lupasol ® SN.
- Example 3.7 Preparation of outer coating layer comprising heparin functionalized PPI G5 dendrimer on underlayer comprising Lupasol ® SN
- the luminal surface of a PVC tubing (I.D. 3 mm) was cleaned with isopropanol and an oxidizing agent.
- the priming was built-up by alternated adsorption of a positively charged polyamine (Lupasol ® SN, 5 wt% in water) and negatively charged sulfated polysaccharide (dextran sulfate, 6 wt% in water).
- the polyamine was crosslinked with a difunctional aldehyde (crotonaldehyde). Every pair of polyamine and sulfated polysaccharide is called one bilayer.
- the PVC surface was primed with 3 bilayers and one layer of Lupasol ® SN.
- Heparin functionalized PPI G5 dendrimer (425 mg/L) from Example 5.7 was deposited onto the positively charged Lupasol ® SN coating for 1 hour followed by a borate/phosphate rinse to remove any loosely bound heparin conjugate prior to evaluation of the non-thrombogenic effect of the coating.
- Aldehyde functionalized heparin is prepared essentially as in Example 2 of USP 4,613,665.
- Nitrous acid degraded heparin with aldehyde groups (prepared essentially as in Example 2 of US 4,613,665) (5.00 g, 1.0 mmol), cysteamine hydrochloride (0.57 g, 5.0 mmol) and sodium chloride (0.6 g) were dissolved in purified water. The pH was adjusted to 6.0 with 1 M NaOH (aq) and 1 M HCI (aq). To the solution was added 3.1 ml of 5 % (aq) NaCNBH 3 (0.16 g, 2.5 mmol) and the reaction was stirred over night at room temperature.
- the pH was adjusted to 1 1.0 with 1 M NaOH (aq) and the resulting product was dialyzed against purified water with a SpectraPor dialysis membrane (MWCO 1 kD, flat width 45mm) for three days.
- the reaction mixture was then concentrated and freeze dried to obtain 2.6 g of a white fluffy powder.
- Alkyne functionalized nitrous acid degraded heparin is prepared essentially as in Example 3a of WO2010/029189.
- Azide functionalized nitrous acid degraded heparin and azide functionalized native heparin is prepared essentially as in Example 4 of WO2010/029189.
- Example 5 Derivatized hvperbranched polymers
- Example 5.1 Preparation of alkene functionalized PAMAM-G6.0-NH 2 dendrimer
- Example 5.2 Preparation of heparin functionalized PAMAM-G6.0-NH 2 dendrimer with preserved specific activity
- the content of the dialysis bag was thereafter transferred to a round bottom flask and lyophilized over night.
- the dry weight of the content in the flask was 830 mg (-60 heparin chains/PAMAM-G6.0-NH 2 dendrimer or 23% functionalization of the primary amines in PAMAM-G6.0-NH 2 ).
- the specific activity of the PAMAM bound heparin in the conjugate was determined to be > 100 lU/mg.
- the heparin used for the preparation, prior to coupling, has a specific activity of approximately 100 lU/mg.
- Azide functionalized Lupasol ® WF can be prepared essentially as described for Lupasol ® SN in Example 2a of WO2010/029189
- Alkyne functionalized Lupasol ® WF can be prepared essentially as described for Lupasol ® SN in Example 2b of WO2010/029189
- Example 5.6 Preparation of heparin functionalized PAMAM-G8.0-NH 2 dendrimer with preserved specific activity
- Heparin functionalized PAMAM-G8.0-NH 2 was prepared essentially as described in Example 5:2.
- Heparin functionalized PPI G5 dendrimer was prepared essentially as described in Example 5:2.
- Hyperbranched polymers with chemical groups, or functionalities, selected from Table 3 may be prepared by a person skilled in the art.
- Non-thrombogenic entities e.g. heparin
- chemical groups, or functionalities selected from Table 3 (Func. 1 and Func. 2) may be prepared by a person skilled in the art.
- the functionalized hyperbranched polymers may be reacted with a functionalized non- thrombogenic entity (e.g. heparin) by a person skilled in the art to yield a hyperbranched polymer derivatised with a non-thromogenic entity (e.g. heparin).
- a functionalized non- thrombogenic entity e.g. heparin
- a non-thromogenic entity e.g. heparin
- Heparin distribution is evaluated using Toluidine blue staining solutions.
- the solution was prepared by dissolving 200 mg of Toluidine blue in 1 L of water. The samples were subjected to the staining solution for 2 minutes prior to extensive water rinse.
- a blue/violet staining indicates that negatively charged heparin molecules are homogenously distributed in the outer coating layer as exemplified by Figure 9 plate B.
- Example 6.1 Coating properties in terms of heparin density and platelet loss, after blood exposure, of the non-thrombogenic surface
- the number of platelets present after the blood was exposed to the non-thrombogenic surface coating was calculated as a percentage of the number of platelets present before the blood was exposed to the non-thrombogenic surface coating and is presented graphically for various samples in Figure 8.
- Example 6.2 Staining of a non-thrombogenic surface using Toluidine blue
- Example 6.3 Staining of a non-thrombogenic surface using Toluidine blue
- Tubing from Example 3.2 was subjected to Toluidine blue stain solution (200 mg/L in water) by immersing in the solution for 2 minutes followed by extensive water rinse. A blue/violet color was observed on the surface of the luminal surface of the tubing indicating the covalent attachment of end-point functionalized heparin in the PAMAM-heparin conjugate.
- the staining of the luminal surface of the PVC-tubing can be seen in Figure 9.
- Example 6.4 Staining of a non-thrombogenic surface using Toluidine blue
- Tubing from Example 3.3 was subjected to Toluidine blue stain solution (200 mg/L in water) by immersing in the solution for 2 minutes followed by extensive water rinse. A blue/violet color was observed on the surface of the luminal surface of the tubing indicating the covalent attachment of end-point functionalized heparin in the PAMAM-heparin conjugate.
- Example 8.1 A hydrophilic and lubricious coating comprising Lupasol ® SK and
- Example 8.2 A hydrophilic and lubricious containing coating comprising Lupasol ® SK, Lupasol ® WF and heparin
- Example 9.1 Incorporation of doxorubicin into a heparinized coating
- Doxorubicin was incorporated into a coating on a QCM crystal, prepared essentially as
- Example 2.3 by placing the QCM crystal in a water solution of doxorubicin (1 mg/25mL of water). The loading step was followed by careful rinsing of the drug loaded coating using water prior to fluorescent evaluation of the coating. The crystal was dried in a vacuum oven prior to fluorescent evaluation. A strong red fluorescence could be detected indicating that doxorubicin was successfully incorporated into the coating.
- Example 9.2 Incorporation of doxorubicin and the subsequent release from a coating comprising heparinized PAMAM-G6.0-NH 2 dendrimer, Lupasol ® SK and Lupasol ® WF Doxorubicin was incorporated into a coating on a QCM crystal, prepared essentially as Example 3.2, by placing the QCM crystal in a water solution of doxorubicin (1 mg/25ml_ of water). The loading step was followed by careful rinsing of the drug loaded coating using water prior to fluorescent evaluation of the coating. The crystal was dried in a vacuum oven prior to fluorescent evaluation. A strong red fluorescence could be detected indicating that doxorubicin was successfully incorporated into the coating.
- Example 9.3 Incorporation of doxorubicin and the subsequent release from a coating comprising heparinized PAMAM-G6.0-NH 2 dendrimer and Lupasol ® WF
- Doxorubicin may be incorporated into a QCM crystal, prepared essentially as Example 3.3, by placing the QCM crystal in a water solution of doxorubicin (1 mg/25ml_ of water) followed by careful rinsing of the drug loaded coating using water prior to fluorescent evaluation of the coating. A strong red fluorescence indicates that doxorubicin was successfully incorporated into the coating. The drug loaded coating was subjected to a 2M NaCI-solution followed by drying in vacuum oven prior to an additional fluorescent microscopy evaluation. The lack of red fluorescence indicated that the doxorubicin had been eluted out from the coating.
- Example 10 Biocompatibility study
- HDPE sheets (30 cm 2 , USP reference standard) were cleaned with isopropanol and an oxidising method. The sheets were then primed as in Example 1 with 3 bilayers ending with sulfated polysaccharide. The priming layers were reacted as in Example 2 with a
- Example 10.1 hyperbranched polyamine followed by a coupling step where functionalized heparin was attached or as in Example 3 first with a polyamine layer followed by a heparin functionalized hyperbranched polymer with net negative charge.
- the coating was performed by immersing the materials into the coating solutions. The coatings were found to be non-toxic in a cytotoxicity testing using the Minimal Essential Medium (MEM) elution test as described in ISO10993 (see Example 10.1).
- MEM Minimal Essential Medium
- Example 11 Hemo-compatibility of EO sterilized coatings comprising hyperbranched polymers
- EO-sterilization was performed using a standard sterilization process used for medical devices. Blood loop evaluation test (for measurement of platelet loss)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020137026084A KR101933237B1 (en) | 2011-03-11 | 2012-03-09 | Improvements to immobilised biological entities |
JP2013557128A JP6251039B2 (en) | 2011-03-11 | 2012-03-09 | Improving immobilized biological components |
AU2012228421A AU2012228421B9 (en) | 2011-03-11 | 2012-03-09 | Improvements to immobilised biological entities |
CA2828797A CA2828797C (en) | 2011-03-11 | 2012-03-09 | Single point attachment of heparin to hyperbranched polymers and coatings thereof |
ES12708138.8T ES2682482T3 (en) | 2011-03-11 | 2012-03-09 | Improvements for immobilized biological entities |
EP18170238.2A EP3375462B1 (en) | 2011-03-11 | 2012-03-09 | Improvements to immobilised biological entities |
RU2013145487A RU2625756C2 (en) | 2011-03-11 | 2012-03-09 | Advanced immobilized biological objects |
CN201280012639.0A CN103596603B (en) | 2011-03-11 | 2012-03-09 | The improvement of fixing biological entities |
BR112013023241-2A BR112013023241B1 (en) | 2011-03-11 | 2012-03-09 | Hyper-branched cationic polymer molecule and device |
EP12708138.8A EP2683420B1 (en) | 2011-03-11 | 2012-03-09 | Improvements to immobilised biological entities |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161451732P | 2011-03-11 | 2011-03-11 | |
US61/451,732 | 2011-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012123384A1 true WO2012123384A1 (en) | 2012-09-20 |
Family
ID=45814511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/054179 WO2012123384A1 (en) | 2011-03-11 | 2012-03-09 | Improvements to immobilised biological entities |
Country Status (10)
Country | Link |
---|---|
US (5) | US9101696B2 (en) |
EP (2) | EP2683420B1 (en) |
JP (5) | JP6251039B2 (en) |
KR (1) | KR101933237B1 (en) |
CN (2) | CN105664252B (en) |
BR (1) | BR112013023241B1 (en) |
CA (1) | CA2828797C (en) |
ES (2) | ES2955183T3 (en) |
RU (1) | RU2625756C2 (en) |
WO (1) | WO2012123384A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015138862A1 (en) | 2014-03-13 | 2015-09-17 | W.L Gore & Associates, Inc. (Us) | Implantable medical device |
JP2016533409A (en) * | 2013-10-02 | 2016-10-27 | フリードリヒ−シラー−ユニバーシタット イエナ | NOVEL POLY (ETHYLENEIMINE) COPOLYMERS FOR BINDING AND RELEASE OF GENETIC MATERIALS, IN particular DNA / RNA, AND PROCESS AND USE OF THE PRODUCT |
WO2019170858A1 (en) | 2018-03-09 | 2019-09-12 | Carmeda Ab | Improvements to processes for immobilising biological entities |
WO2019170859A2 (en) | 2018-03-09 | 2019-09-12 | Carmeda Ab | Improvements to immobilising biological entities |
WO2020070258A1 (en) | 2018-10-03 | 2020-04-09 | Carmeda Ab | Immobilised biological entities |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101933237B1 (en) | 2011-03-11 | 2018-12-27 | 더블유.엘. 고어 앤드 어소시에이트스, 인코포레이티드 | Improvements to immobilised biological entities |
US9283072B2 (en) | 2012-07-25 | 2016-03-15 | W. L. Gore & Associates, Inc. | Everting transcatheter valve and methods |
US9968443B2 (en) | 2012-12-19 | 2018-05-15 | W. L. Gore & Associates, Inc. | Vertical coaptation zone in a planar portion of prosthetic heart valve leaflet |
US9144492B2 (en) | 2012-12-19 | 2015-09-29 | W. L. Gore & Associates, Inc. | Truncated leaflet for prosthetic heart valves, preformed valve |
US9101469B2 (en) | 2012-12-19 | 2015-08-11 | W. L. Gore & Associates, Inc. | Prosthetic heart valve with leaflet shelving |
KR102247959B1 (en) | 2013-02-04 | 2021-05-06 | 더블유.엘. 고어 앤드 어소시에이트스, 인코포레이티드 | Coating for substrate |
RU2679615C1 (en) * | 2013-11-28 | 2019-02-12 | Торэй Индастриз, Инк. | Antithrombotic material |
CN103832021B (en) * | 2014-01-09 | 2016-03-02 | 西南交通大学 | Organic molecule hydridization TiO is prepared in a kind of titanium substrate 2the method of nano compound film |
GR20140100263A (en) * | 2014-05-02 | 2016-02-01 | Εκεφε Δημοκριτος | Innovative carbon-based materials modified with dendritic polymers exhibiting anti-bacterial action and/or influence to the photosynthetic operation |
KR102370116B1 (en) * | 2014-05-09 | 2022-03-04 | 도레이 카부시키가이샤 | Endovascular treatment assistance tool |
WO2015188716A1 (en) * | 2014-06-09 | 2015-12-17 | 上海微创医疗器械(集团)有限公司 | Anticoagulation coating and applying method therefor |
RU2711652C2 (en) * | 2015-03-31 | 2020-01-17 | Торэй Индастриз, Инк. | Antithrombotic metal material |
EP3095509A1 (en) * | 2015-05-18 | 2016-11-23 | Defymed | Membranes functionalized with heparin for bioartificial organs |
EP3305342A4 (en) * | 2015-05-27 | 2019-02-06 | Toray Industries, Inc. | Antithrombotic material |
CN106730051B (en) * | 2016-12-27 | 2020-05-01 | 生纳科技(上海)有限公司 | Anticoagulation polymer biological material and preparation method and application thereof |
EP3577179A4 (en) * | 2017-01-31 | 2020-01-08 | The Regents of The University of California | Multi-arm block-copolymers for multifunctional self-assembled systems |
CA3178271A1 (en) | 2017-09-27 | 2019-04-04 | W.L. Gore & Associates, Inc. | Prosthetic valve with expandable frame and associated systems and methods |
JP7429191B2 (en) * | 2018-03-07 | 2024-02-07 | フォルシュングスフェアバント ベルリン エー.ベー. | Chemoselective thiol conjugation with alkene phosphonothiolates or alkyne phosphonothiolates and alkene phosphonates or alkyne phosphonates |
EP3781222A4 (en) * | 2018-04-20 | 2022-01-26 | Ension, Inc. | Engineered heparin bioactive matrix for clinical application of blood contacting surface and method of manufacturing the same |
US11497601B2 (en) | 2019-03-01 | 2022-11-15 | W. L. Gore & Associates, Inc. | Telescoping prosthetic valve with retention element |
CN110028692B (en) * | 2019-03-14 | 2020-11-03 | 江苏赛腾医疗科技有限公司 | Preparation method of surface heparinization anticoagulant medical device based on ionic bond-covalent bond cooperation |
CN110464882A (en) * | 2019-07-29 | 2019-11-19 | 东华大学 | A kind of ureter rack tube and preparation method thereof that hydrophilic antimicrobial is degradable |
US20220273426A1 (en) | 2019-08-01 | 2022-09-01 | W. L. Gore & Associates, Inc. | Transcatheter prosthetic valve with multi-part frame subcomponent transverse deformation resistance |
AU2020327031B2 (en) | 2019-08-07 | 2023-10-05 | W. L. Gore & Associates, Inc. | Balloon delivery device for a light activable treatment media |
CN111544646A (en) * | 2020-03-30 | 2020-08-18 | 东华大学 | Small-caliber artificial blood vessel with surface grafted with heparin coating and preparation method thereof |
CN117616130A (en) | 2021-04-19 | 2024-02-27 | W.L.戈尔及同仁股份有限公司 | Electrochemical analyte biosensors, related compositions of matter, and methods of making and using the same |
EP4333922A1 (en) * | 2021-05-04 | 2024-03-13 | Institut national de la santé et de la recherche médicale (INSERM) | New devices for use for treating cerebral aneurysms |
CN117500484A (en) | 2021-06-08 | 2024-02-02 | W.L.戈尔及同仁股份有限公司 | Therapeutic medium delivery device and method for targeted delivery thereof |
CN114392738B (en) * | 2022-01-25 | 2023-01-10 | 同济大学 | Covalent heteroligand, alkynyl hyperbranched polyethyleneimine mineralization method for modulating gold nanoclusters, method and application |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0086187A1 (en) | 1982-02-09 | 1983-08-17 | I.R.D. Biomaterial Aktiebolag | A surface modified solid substrate and a method for its preparation |
EP0086186B1 (en) | 1982-02-09 | 1986-05-21 | Olle Larm | A process for covalent coupling for the production of conjugates, and products hereby obtained |
US4944767A (en) | 1986-01-16 | 1990-07-31 | G. Creamascoli S.P.A. | Synthetic material apt to stably adsorb high quantities of heparin, and process for the production thereof |
EP0495820A1 (en) | 1989-10-12 | 1992-07-29 | Norsk Hydro As | Process for the preparation of surface modified solid substrates. |
US5527524A (en) * | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
WO2001041827A1 (en) * | 1999-12-07 | 2001-06-14 | Navid Malik | Internally supported biomimetic materials and coatings |
US6461665B1 (en) | 1998-09-09 | 2002-10-08 | Carmeda Ab | Process for preparing surface modification substances |
US20030135195A1 (en) | 2002-01-16 | 2003-07-17 | Oscar Jimenez | Highly lubricious hydrophilic coating utilizing dendrimers |
WO2003057270A1 (en) | 2002-01-09 | 2003-07-17 | Novartis Ag | Polymeric articles having a lubricous coating |
US6653457B1 (en) | 1999-11-23 | 2003-11-25 | Medicarb Ab | Method of covalent coupling |
US20050059068A1 (en) | 2001-05-23 | 2005-03-17 | Stratagene California | Compositions and methods using dendrimer-treated microassays |
US20070264308A1 (en) | 2006-05-12 | 2007-11-15 | Cleek Robert L | Immobilized Biologically Active Entities Having High Biological Activity Following Mechanical Manipulation |
WO2008063157A2 (en) * | 2006-10-25 | 2008-05-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | A nanoparticle-based anticoagulant |
US20080267903A1 (en) * | 2004-10-14 | 2008-10-30 | Ijeoma Uchegbu | Bioactive Polymers |
US20090274737A1 (en) | 2008-05-02 | 2009-11-05 | Biotronik Vi Patent Ag | Implant comprising a surface of reduced thrombogenicity |
WO2010029189A2 (en) | 2008-09-15 | 2010-03-18 | Carmeda Ab | Immobilised biological entities |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE392582B (en) | 1970-05-21 | 1977-04-04 | Gore & Ass | PROCEDURE FOR THE PREPARATION OF A POROST MATERIAL, BY EXPANDING AND STRETCHING A TETRAFLUORETENE POLYMER PREPARED IN AN PASTE-FORMING EXTENSION PROCEDURE |
JPS6041948B2 (en) | 1977-12-15 | 1985-09-19 | ユニチカ株式会社 | Method for imparting antithrombotic properties to solid surfaces |
US4415490A (en) | 1979-07-24 | 1983-11-15 | Nippon Zeon Co., Ltd. | Non-thrombogenic material |
US4329383A (en) | 1979-07-24 | 1982-05-11 | Nippon Zeon Co., Ltd. | Non-thrombogenic material comprising substrate which has been reacted with heparin |
US4326532A (en) | 1980-10-06 | 1982-04-27 | Minnesota Mining And Manufacturing Company | Antithrombogenic articles |
US4678671A (en) | 1981-12-15 | 1987-07-07 | Cordis Europa N.V. | Conjugates of anticoagulant and protein |
US4526714A (en) | 1982-12-13 | 1985-07-02 | Cordis Europa N.V. | Conjugates of anticoagulant and protein |
US4600652A (en) | 1985-04-01 | 1986-07-15 | Warner-Lambert Company | Permanently bonded antithrombogenic polyurethane surface |
SE452551B (en) | 1986-05-27 | 1987-12-07 | Camurus Ab | ARTICLE COVERED WITH HEPARIN BASED MATERIAL AND PROCEDURE FOR ITS MANUFACTURING |
US4745180A (en) | 1986-06-27 | 1988-05-17 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using heparin fragments |
US5308617A (en) | 1988-08-10 | 1994-05-03 | Halzyme Ltd. | Protein heparin conjugates |
US5130143A (en) | 1988-11-04 | 1992-07-14 | The Research Foundation Of State University Of New York | Use of a low affinity-heparin fraction in conjunction with t-pa for thrombolytic therapy |
US5510418A (en) | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5032666A (en) | 1989-06-19 | 1991-07-16 | Becton, Dickinson And Company | Amine rich fluorinated polyurethaneureas and their use in a method to immobilize an antithrombogenic agent on a device surface |
US5213898A (en) | 1989-10-12 | 1993-05-25 | Norsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
WO1993005825A1 (en) | 1991-09-20 | 1993-04-01 | Baxter International Inc. | Processes for reducing the thrombogenicity of biomaterials |
SE470006B (en) | 1991-09-26 | 1993-10-25 | Corline Systems Ab | New conjugate, its preparation and use, and substrates prepared with the conjugate |
IT1254898B (en) | 1992-04-21 | 1995-10-11 | Gianfranco Palumbo | POLYETEREAMIDOAMINE TYPE HYDROGEL AS EPARINIZABLE MATERIALS |
US5532311A (en) | 1995-02-01 | 1996-07-02 | Minnesota Mining And Manufacturing Company | Process for modifying surfaces |
US6120536A (en) | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5583213A (en) | 1995-05-12 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Process to activate sulfated polysaccharides |
US5679659A (en) | 1995-08-22 | 1997-10-21 | Medtronic, Inc. | Method for making heparinized biomaterials |
US5767108A (en) | 1995-08-22 | 1998-06-16 | Medtronic, Inc. | Method for making improved heparinized biomaterials |
US7045585B2 (en) | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
GB9526546D0 (en) | 1995-12-23 | 1996-02-28 | Pfizer Ltd | Compounds useful in therapy |
US5922690A (en) | 1996-04-25 | 1999-07-13 | Van Gorp; Cornelius L. | Dermatan disulfate, an inhibitor of thrombin generation and activation |
US7034061B1 (en) * | 1996-04-30 | 2006-04-25 | Ajay Kumar Luthra | Non-thrombogenic and anti-thrombogenic polymers |
GB9608882D0 (en) | 1996-04-30 | 1996-07-03 | Luthra Ajay K | Non-thrombogenic and anti-thrombogenic polymers |
US5876433A (en) | 1996-05-29 | 1999-03-02 | Ethicon, Inc. | Stent and method of varying amounts of heparin coated thereon to control treatment |
US5914182A (en) | 1996-06-03 | 1999-06-22 | Gore Hybrid Technologies, Inc. | Materials and methods for the immobilization of bioactive species onto polymeric substrates |
US5916585A (en) | 1996-06-03 | 1999-06-29 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto biodegradable polymers |
US5728751A (en) | 1996-11-25 | 1998-03-17 | Meadox Medicals, Inc. | Bonding bio-active materials to substrate surfaces |
JPH114883A (en) | 1997-06-18 | 1999-01-12 | Toray Ind Inc | Anti-thrombogenic medical material |
JP2003506310A (en) | 1997-10-07 | 2003-02-18 | リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Treatment of occlusive peripheral vascular disease and coronary artery disease with a combination of heparin and an adenosine A2 agonist or with adenosine |
FI974321A0 (en) | 1997-11-25 | 1997-11-25 | Jenny Ja Antti Wihurin Rahasto | Multiple heparinglycosaminoglycans and proteoglycans are used |
AU761192B2 (en) | 1998-06-10 | 2003-05-29 | Converge Medical, Inc. | Sutureless anastomosis systems |
GB9814420D0 (en) | 1998-07-03 | 1998-09-02 | Cancer Res Campaign Tech | Sequence analysis of saccharide material |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
MXPA01010692A (en) | 1999-04-22 | 2004-09-06 | Univ Zuerich | Modified protein matrices. |
ES2225243T3 (en) | 1999-10-19 | 2005-03-16 | Commonwealth Scientific And Industrial Research Organisation | PREPARATION OF A FUNCTIONAL POLYMERIC SURFACE. |
US7736687B2 (en) | 2006-01-31 | 2010-06-15 | Advance Bio Prosthetic Surfaces, Ltd. | Methods of making medical devices |
US6936066B2 (en) | 1999-11-19 | 2005-08-30 | Advanced Bio Prosthetic Surfaces, Ltd. | Complaint implantable medical devices and methods of making same |
US6518244B2 (en) | 2000-03-09 | 2003-02-11 | Intimax Corporation | Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof |
US7875283B2 (en) | 2000-04-13 | 2011-01-25 | Advanced Cardiovascular Systems, Inc. | Biodegradable polymers for use with implantable medical devices |
AU5574101A (en) | 2000-04-28 | 2001-11-12 | Univ Emory | Decellularized vascular prostheses |
ES2250408T3 (en) | 2000-05-12 | 2006-04-16 | Cordis Corporation | ADMINISTRATION DEVICES FOR THE TREATMENT OF VASCULAR DISEASES. |
US6509104B2 (en) | 2000-12-05 | 2003-01-21 | Michigan Biotechnology Institute | Antithrombogenic polymer coating |
US6787179B2 (en) | 2001-06-29 | 2004-09-07 | Ethicon, Inc. | Sterilization of bioactive coatings |
JP2005044408A (en) | 2003-07-24 | 2005-02-17 | Pioneer Electronic Corp | Optical integrated device and optical pickup device |
WO2005018552A2 (en) | 2003-08-12 | 2005-03-03 | University Of Utah Research Foundation | Heparin binding proteins: sensors for heparin detection |
WO2005099786A1 (en) | 2004-04-06 | 2005-10-27 | Surmodics, Inc. | Coating compositions for bioactive agents |
JP5178506B2 (en) | 2005-03-14 | 2013-04-10 | バイオベンション ホールディングス リミテッド | Methods related to drug delivery compositions |
US7767420B2 (en) | 2005-11-03 | 2010-08-03 | Momenta Pharmaceuticals, Inc. | Heparan sulfate glycosaminoglycan lyase and uses thereof |
EP1834636A1 (en) | 2006-03-08 | 2007-09-19 | Sahajanand Medical Technologies PVT. ltd | Compositions comprising porous articles and uses in implantable medical devices |
ES2623602T3 (en) | 2006-05-12 | 2017-07-11 | W. L. Gore & Associates, Inc. | Biologically active immobilized entities that have a high degree of biological activity after mechanical manipulation or sterilization |
US9114194B2 (en) | 2006-05-12 | 2015-08-25 | W. L. Gore & Associates, Inc. | Immobilized biologically active entities having high biological activity following mechanical manipulation |
US20080279909A1 (en) | 2006-05-12 | 2008-11-13 | Cleek Robert L | Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization |
GB201004101D0 (en) | 2010-03-12 | 2010-04-28 | Carmeda Ab | Immobilised biological entities |
KR101933237B1 (en) | 2011-03-11 | 2018-12-27 | 더블유.엘. 고어 앤드 어소시에이트스, 인코포레이티드 | Improvements to immobilised biological entities |
GB2508574B (en) | 2012-06-24 | 2014-12-17 | Fasmatech Science And Technology Sa | Improvements in and relating to the control of ions |
-
2012
- 2012-03-09 KR KR1020137026084A patent/KR101933237B1/en active IP Right Grant
- 2012-03-09 CN CN201511008867.2A patent/CN105664252B/en active Active
- 2012-03-09 JP JP2013557128A patent/JP6251039B2/en active Active
- 2012-03-09 ES ES18170238T patent/ES2955183T3/en active Active
- 2012-03-09 EP EP12708138.8A patent/EP2683420B1/en active Active
- 2012-03-09 EP EP18170238.2A patent/EP3375462B1/en active Active
- 2012-03-09 ES ES12708138.8T patent/ES2682482T3/en active Active
- 2012-03-09 CA CA2828797A patent/CA2828797C/en active Active
- 2012-03-09 CN CN201280012639.0A patent/CN103596603B/en active Active
- 2012-03-09 US US13/416,880 patent/US9101696B2/en active Active
- 2012-03-09 WO PCT/EP2012/054179 patent/WO2012123384A1/en unknown
- 2012-03-09 BR BR112013023241-2A patent/BR112013023241B1/en not_active IP Right Cessation
- 2012-03-09 RU RU2013145487A patent/RU2625756C2/en active
-
2015
- 2015-07-02 US US14/790,205 patent/US9408950B2/en active Active
-
2016
- 2016-07-07 US US15/204,128 patent/US9764068B2/en active Active
-
2017
- 2017-08-23 US US15/684,007 patent/US10736999B2/en active Active
- 2017-11-24 JP JP2017225620A patent/JP6643298B2/en active Active
-
2019
- 2019-09-05 JP JP2019161946A patent/JP2019202226A/en active Pending
-
2020
- 2020-06-26 US US16/914,085 patent/US11497838B2/en active Active
- 2020-11-25 JP JP2020195102A patent/JP7222963B2/en active Active
-
2022
- 2022-12-08 JP JP2022196345A patent/JP2023017012A/en active Pending
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0086187B1 (en) | 1982-02-09 | 1985-10-23 | I.R.D. Biomaterial Aktiebolag | A surface modified solid substrate and a method for its preparation |
EP0086186B1 (en) | 1982-02-09 | 1986-05-21 | Olle Larm | A process for covalent coupling for the production of conjugates, and products hereby obtained |
US4613665A (en) | 1982-02-09 | 1986-09-23 | Olle Larm | Process for covalent coupling for the production of conjugates, and polysaccharide containing products thereby obtained |
EP0086187A1 (en) | 1982-02-09 | 1983-08-17 | I.R.D. Biomaterial Aktiebolag | A surface modified solid substrate and a method for its preparation |
US4944767A (en) | 1986-01-16 | 1990-07-31 | G. Creamascoli S.P.A. | Synthetic material apt to stably adsorb high quantities of heparin, and process for the production thereof |
US5527524A (en) * | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
EP0495820A1 (en) | 1989-10-12 | 1992-07-29 | Norsk Hydro As | Process for the preparation of surface modified solid substrates. |
EP0495820B1 (en) | 1989-10-12 | 1995-05-17 | Norsk Hydro A/S | Process for the preparation of surface modified solid substrates |
US6461665B1 (en) | 1998-09-09 | 2002-10-08 | Carmeda Ab | Process for preparing surface modification substances |
US6653457B1 (en) | 1999-11-23 | 2003-11-25 | Medicarb Ab | Method of covalent coupling |
WO2001041827A1 (en) * | 1999-12-07 | 2001-06-14 | Navid Malik | Internally supported biomimetic materials and coatings |
US20050059068A1 (en) | 2001-05-23 | 2005-03-17 | Stratagene California | Compositions and methods using dendrimer-treated microassays |
WO2003057270A1 (en) | 2002-01-09 | 2003-07-17 | Novartis Ag | Polymeric articles having a lubricous coating |
US20030135195A1 (en) | 2002-01-16 | 2003-07-17 | Oscar Jimenez | Highly lubricious hydrophilic coating utilizing dendrimers |
US20080267903A1 (en) * | 2004-10-14 | 2008-10-30 | Ijeoma Uchegbu | Bioactive Polymers |
US20070264308A1 (en) | 2006-05-12 | 2007-11-15 | Cleek Robert L | Immobilized Biologically Active Entities Having High Biological Activity Following Mechanical Manipulation |
WO2008063157A2 (en) * | 2006-10-25 | 2008-05-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | A nanoparticle-based anticoagulant |
US20090274737A1 (en) | 2008-05-02 | 2009-11-05 | Biotronik Vi Patent Ag | Implant comprising a surface of reduced thrombogenicity |
WO2010029189A2 (en) | 2008-09-15 | 2010-03-18 | Carmeda Ab | Immobilised biological entities |
Non-Patent Citations (7)
Title |
---|
"Bioconjugate techniques", 2008 |
"Dendrimers: building blocks for nanoscale synthesis", ALDRICHIMICA ACTA, vol. 37, no. 2, 2004, pages 1 - 52 |
ANDERSSON, J.; SANCHEZ, J.; EKDAHL, K. N.; ELGUE, G.; NILSSON, B.; LARSSON, R., J BIOMED MATER RES A, vol. 67, no. 2, 2003, pages 458 - 466 |
MULTILAYER THIN FILMS |
PASCHE ET AL.: "Binding of antithrombin to immobilized heparin under varying flow conditions", ARTIF. ORGANS, vol. 15, 1991, pages 481 - 491 |
SANCHEZ ET AL., J. BIOMED. MATER. RES., vol. 37, no. 1, 1997, pages 37 - 42 |
SMITH R. L.; GILKERSON E, ANAL. BIOCHEM., vol. 98, 1979, pages 478 - 480 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016533409A (en) * | 2013-10-02 | 2016-10-27 | フリードリヒ−シラー−ユニバーシタット イエナ | NOVEL POLY (ETHYLENEIMINE) COPOLYMERS FOR BINDING AND RELEASE OF GENETIC MATERIALS, IN particular DNA / RNA, AND PROCESS AND USE OF THE PRODUCT |
WO2015138862A1 (en) | 2014-03-13 | 2015-09-17 | W.L Gore & Associates, Inc. (Us) | Implantable medical device |
US11839698B2 (en) | 2014-03-13 | 2023-12-12 | W. L. Gore & Associates, Inc. | Drug composition and coating |
WO2019170858A1 (en) | 2018-03-09 | 2019-09-12 | Carmeda Ab | Improvements to processes for immobilising biological entities |
WO2019170859A2 (en) | 2018-03-09 | 2019-09-12 | Carmeda Ab | Improvements to immobilising biological entities |
WO2020070258A1 (en) | 2018-10-03 | 2020-04-09 | Carmeda Ab | Immobilised biological entities |
US11850334B2 (en) | 2018-10-03 | 2023-12-26 | Carmeda Ab | Immobilised biological entities |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11497838B2 (en) | Immobilised biological entities | |
US10842880B2 (en) | Immobilised biological entities | |
AU2012228421B9 (en) | Improvements to immobilised biological entities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12708138 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012228421 Country of ref document: AU Date of ref document: 20120309 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2828797 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013557128 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137026084 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013145487 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013023241 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013023241 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130911 |